WO2024086791A2

WO2024086791A2 - Chimeric receptors and uses thereof

Info

Publication number: WO2024086791A2
Application number: PCT/US2023/077412
Authority: WO
Inventors: Lee Andrew Boland SWANSON; Huang ZHU
Original assignee: Shoreline Biosciences, Inc.
Priority date: 2022-10-21
Filing date: 2023-10-20
Publication date: 2024-04-25
Also published as: WO2024086791A3

Abstract

Provided herein at chimeric receptors comprising an IgG Fc receptor and toll/interleukin- 1 receptor (TIR) signaling domain. Further provided are immune effector cells (e.g., NK cells) expressing said chimeric receptors and methods for using the same.

Description

CHIMERIC RECEPTORS AND USES THEREOF

CROSS REFERENCE

[001] This application claims the benefit of US Provisional Application No. 63/418,220, filed October 21, 2023, and US Provisional Application No. 63/459,052, filed April 13, 2023, the entirety of which are hereby incorporated by reference herein in their entirety.

SEQUENCE LISTING

[002] This application contains a computer readable Sequence Listing which has been submitted in XML file format with this application, the entire content of which is incorporated by reference herein in its entirety. The Sequence Listing XML file submitted with this application is entitled “14735-023-228_SEQLISTING.xml,” was created on October 20, 2023, and is 341,125 bytes in size.

BACKGROUND

[003] Natural Killer (NK) cells are innate immune cells that recognize malignant cells through receptors. Activating certain receptors results in cytotoxicity against the malignant cells and immune system activation. Research efforts have focused on increasing the targeting of therapeutic NK cells toward cancer, for both solid and liquid tumors. Although the field is moving forward, several challenges remain for bringing therapeutic NK cells to human patients. Accordingly, novel strategies are needed to improve the therapeutic efficacy of such cells.

SUMMARY

[004] The present disclosure is based, at least in part, on the discovery of chimeric receptors. Accordingly, in some aspects, the disclosure provides a chimeric receptor comprising from N-terminus to C-terminus:

(i) an extracellular domain comprising a polypeptide derived from an IgG Fc receptor;

(ii) a transmembrane domain; and

(iii) a cytoplasmic domain comprising a Toll/interleukin-1 receptor (TIR) signaling domain.

[005] In some aspects, the disclosure provides a chimeric receptor comprising:

(ii) a transmembrane domain operably linked to the extracellular domain; and (iii) a cytoplasmic domain operably linked to the transmembrane domain, wherein the cytoplasmic domain comprises a Toll/interleukin-1 receptor (TIR) signaling domain.

[0061 In some embodiments, the IgG Fc receptor is selected from CD 16, CD32a, CD32b, CD32c, and CD64. In some embodiments, the polypeptide comprises an ectodomain domain of CD64. In some embodiments, the polypeptide comprises an ectodomain domain of CD 16, or variant thereof.

[007] In some embodiments, the polypeptide derived from the IgG Fc receptor comprises a sequence selected from SEQ ID NO: 38.

[008] In some embodiments, the transmembrane domain is a transmembrane domain of DNAM1, CD64, CD32a, CD32c, 2B4, CD8, CD4, CD3, NTB-A, CD28, IL-2R beta, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, IL-1R or IL-18R, NKG2D, or a functional variant thereof.

[009] In some embodiments, the transmembrane domain of NKG2D is in reverse orientation, optionally wherein the transmembrane domain of NKG2D in reverse orientation comprises the amino acid sequence of SEQ ID NO: 36.

[0010] In some embodiments, the TIR signaling domain is a signaling domain of a Tolldike receptor (TLR) polypeptide. In some embodiments, the TIR signaling domain is a signaling domain of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, or TLR10. In some embodiments, the TIR signaling domain is a signaling domain of TLR2. In some embodiments, the signaling domain of TLR comprises the amino acid sequence set forth in SEQ ID NO: 25. In some embodiments, the TIR signaling domain comprises a sequence selected from SEQ ID NOs: 25, 118, 120, 122, 124, 126, 128, 130, 132 and 134.

[0011] In some embodiments, the TIR signaling domain is a signaling domain of an interleukin-1 receptor (IL-1R) polypeptide. In some embodiments, the TIR signaling domain is a signaling domain of IL-1R, IL-18R, IL-1R4, IL-1R6, IL-1R3, IL-1R7, IL-18R, IL-1R9, or IL- 1R10. In some embodiments, the TIR signaling domain comprises a sequence selected from SEQ ID NOs: 136, 138, 140, 142, 144, 146, 148, 150, and 152.

[0012] In some embodiments, the cytoplasmic domain further comprises an intracellular signaling domain. In some embodiments, the intracellular signaling domain is a signaling domain of CD3zeta or CD137. In some embodiments, the intracellular signaling domain is a signaling domain of CD3zeta, and wherein the signaling domain of CD3zeta comprises the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the intracellular signaling domain is operably linked to the TIR signaling domain with or without a linker. In some embodiments, the C-terminus of the TIR signaling domain is operably linked to the N-terminus of the intracellular signaling domain via a Gly-Ser linker.

[0013] In some embodiments,

(i) the extracellular domain comprises a polypeptide derived from CD64 ectodomain;

(ii) the transmembrane domain is a transmembrane domain of CD28, TLR2, CD64 or NKG2D; and

(ii) the cytoplasmic domain comprises a signaling domain of TLR2.

[0014] In some embodiments, the cytoplasmic domain further comprises a signaling domain of CD3zeta.

[0015] In some embodiments, the chimeric receptor comprises:

(i) a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain;

(ii) a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain;

(iii) a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain; or

(iv) a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain.

[0016] In some embodiments, the C-terminus of the extracellular domain is operably linked to the N-terminus or C-terminus of the transmembrane domain without a linker. In some embodiments, the C-terminus of the extracellular domain is operably linked to the N-terminus or C-terminus of the transmembrane domain with a linker or a hinge domain.

[0017] In some embodiments, the hinge domain is a hinge region of CD8a. In some embodiments, the hinge region of CD8a comprises the amino acid sequence set forth in SEQ ID NO: 154.

[0018] In some embodiments, the N-terminus or C-terminus of the transmembrane domain is operably linked to the N-terminus of the cytoplasmic domain, with or without a linker. In some embodiments, the transmembrane domain is operably linked to the cytoplasmic domain with a Gly-Ser linker. [0019] In some embodiments, the chimeric receptor comprises an amino acid sequence selected from SEQ ID NOs: 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, and 102.

[0020] In some embodiments, the disclosure provides a polynucleotide comprising a nucleotide sequence encoding the chimeric receptor.

[0021] In some embodiments, the disclosure provides a population of cells comprising an immune cell comprising the chimeric receptor. In some embodiments, the immune cell is a natural killer (NK) cell. In some embodiments, the NK cell is an induced pluripotent stem cell- derived natural killer (iPSC-NK) cell.

[0022] In some embodiments, the immune cell comprises a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises an antigen binding domain. In some embodiments, the antigen binding domain is specific for an antigen. In some embodiments, the antigen binding domain is specific for a cancer antigen.

[0023] In some embodiments, the immune cell further comprises an IL- 15 polypeptide. In some embodiments, the IL-15 polypeptide is a fusion protein of a human IL-15 polypeptide operably linked to a human IL-15R polypeptide, with or without a linker. In some embodiments, the human IL- 15 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 17, and the human IL-15R polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 21. In some embodiments, the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 29.

[0024] In some embodiments, the immune cell is CISH^+/+. In some embodiments, the immune cell comprises homozygous inactivating mutations in a cytokine-inducible SH2- containing protein (CISH) gene. In some embodiments, the immune cell comprises heterozygous inactivating mutations in a cytokine-inducible SH2-containing protein (CISH) gene. In some embodiments, the immune cell is CISHA In some embodiments, the immune cell is CISH^+/". In some embodiments, the cell does not comprise homozygous inactivating mutations of the cytokine -inducible SH2 -containing protein (CISH) genes (e.g., is CISH^+/+). In some embodiments, the cell comprises homozygous inactivating mutations of the transforming growth factor beta receptor 2 (TGFBR2) genes (e.g., is TGFBR2 '^/'). In some embodiments, the cell does not comprise homozygous inactivating mutations of the transforming growth factor beta receptor 2 (TGFBR2) genes (e.g., is TGFBR2 ^+/+). In some embodiments, the cell comprises homozygous inactivating mutations of the beta-2-microglobulin (B2M) genes (e.g., is B2M '^/'). In some embodiments, the cell comprises homozygous inactivating mutations of the class JI major histocompatibility complex transactivator (CIITA) genes In some

embodiments, the cell comprises homozygous inactivating mutations of the regulatory factor X (RFX) genes

[0025] In some embodiments, the disclosure provides a pharmaceutical composition comprising the population of cells.

[0026] In some embodiments, the disclosure provides a method of treating cancer in a subject in need thereof, comprising administering a pharmaceutical composition.

[0027] In some embodiments, the disclosure provides a method of enhancing antibodydependent cellular cytotoxicity (ADCC) of an NK cell, comprising engineering the NK cell to express a chimeric receptor. In some embodiments, the NK cell comprises a CAR.

[0028] In some embodiments, the disclosure provides a method of enhancing anti -turn or efficacy of a CAR-expressing immune cell, comprising engineering the CAR-expressing immune cell to express a chimeric receptor, thereby enhancing the anti-tumor efficacy of the CAR-expressing immune cell.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] FIG. 1 illustrates that the exemplary CD64 chimeric receptor construct CD64- NKTM-2B4-CD3zeta-IL15 (“CD64-CAR”) enhances antibody-dependent cellular cytotoxicity (ADCC) in wild-type NK cells derived from induced pluripotent stem cells (WT iNK cells) and CISH knockout iNK cells. Line graph quantification of NK killing against an NK cell resistant solid tumor target BT474 2D cell line (effector: target cell ratio (“E:T”) of 2: 1) (FIG. 1).

[0030] FIG. 2A - FIG. 2F illustrate that the exemplary CD64 chimeric receptor construct CD64-NKTM-2B4-CD3zeta-IL15 enhances ADCC against FaDu spheroids in dose dependent manner. Representative images of target cell spheroid killing after 72 hour co-culture of either untransduced CISH KO iNK cells or CISH KO iNK cells expressing CD64-NKTM-2B4- CD3zeta-IL15, and a NK cell resistant solid tumor FaDu spheroids (E:T 2.5: 1) without or with 10 pg/mL cetuximab (FIG. 2A), or CISH KO iNK cells expressing CD64-NKTM-2B4-CD3zeta- IL15 and FaDu spheroids (E:T 10: 1) without, or with 1 pg/mL, or 10 pg/mL cetuximab (FIG. 2B). Representative images of target cell spheroid killing after 72 hour co-culture of either untransduced CISH KO iNK cells or CISH KO iNK cells expressing CD64-NKTM-2B4- CD3zeta-IL15 and FaDu spheroids with no antibody, 1 pg/mL cetuximab, or 10 pg/mL cetuximab at (E:T 10:1) (FIG. 2C), (E:T 5: 1) (FIG. 2D), or (E:T 2.5: 1) (FIG. 2E). Antibody alone had minimal effect (FIG. 2F). Deterioration of spheroid structural integrity indicates target cell killing.

[0031] FIG. 3A - FIG. 3C illustrate that the exemplary CD64 chimeric receptor construct CD64-NKTM-TLR2-CD3zeta (“CD64-CAR2”) exhibits similar ADCC as cells engineered with high affinity non-cleavable CD16 (hnCD16). Representative images of target cell spheroid killing after 72 hour co-culture of CISH KO iNK cells and BT474 spheroids expressing mKate2 (E:T 2.5: 1) without or with 10 pg/mL trastuzumab (FIG. 3A). Deterioration of spheroid structural integrity indicates target cell killing. Line graph quantification of NK killing against a NK cell resistant solid tumor BT474 spheroids (E:T 20: 1 ) (FIG. 3B). Measurement of CD64- CAR2 and hnCD16 expression at 4 hours, 24 hours, 48 hours, and 72 hours (FIG. 3C).

[0032] FIG. 4A and FIG. 4B illustrate that CISH KO iNK cells expressing the exemplary CD64 chimeric receptor construct CD64-CAR2 have greater ADCC activity with low doses of a therapeutic antibody (e.g., trastuzumab) after 48 hours of killing BT474 spheroids (E:T 10: 1), relative to CISH KO iNK cells expressing hnCD16 or hCD16 under the same conditions (FIG. 4B). Expression of the indicated constructs was measured at the start of the killing (FIG. 4A). [0033] FIG. 5A - FIG. 5D illustrate that CISH KO iNK cells expressing the exemplary CD64 chimeric receptor constructs CD64-CAR2 (FIG. 5 A) and CD64-CD16TM-linker-CD16 (“CD64-CD16”) (FIG. 5B) have greater basal activity and greater ADCC activity with low doses of a therapeutic antibody (e.g., trastuzumab) after 24 hours of killing BT474 spheroids, relative to CISH KO iNK cells expressing hnCD16 (FIG. 5C) or hCD16 (FIG. 5D) under the same conditions.

[0034] FIG. 6A and FIG. 6B illustrate that the exemplary CD64 chimeric receptor constructs CD64-CAR2 and CD64-TLR2TM-TLR2MP-TLR2-linker-CD3zeta (hereinafter “CD64-TLR2TM-TLR2-CD3zeta” or “CD64-CAR3”) do not affect function of the CISH KO iNK cells after 60 hours of killing BT474 spheroids (E:T 20: 1) (FIG. 6B), when compared to the exemplary CD64 chimeric receptor construct CD64-NKTM-2B4-CD3zeta (“CD64-CAR4”). Expression of the CD64 chimeric receptor constructs was measured for over 72 hours (CD64- CAR4, left column; CD64-CAR2 middle column; CD64-CAR3 right column) (FIG. 6B). [0035] FTG. 7A - FIG. 7F illustrate that serum TgG (0, 2, 4, or 8 mg/mL) delays but does not inhibit ADCC mediated killing (E:T 7.5: 1) following mRNA delivery of CD64-CAR2 (FIG. 7A), hCD16 (FIG. 7B), CD64-CD16 (FIG. 7C), or hnCD16 (FIG. 7D), relative to cells without a construct (WT) (FIG. 7A), and summarized in FIG. 7F.

[0036] FIG. 8A - FIG. 8E illustrate that serum IgG (0 mg/mL (FIG. 8B); 2 mg/mL (FIG. 8C); 4 mg/mL (FIG. 8D); 8 mg/mL (FIG. 8E)) delays but does not inhibit ADCC mediated killing (E:T 7.5: 1) following mRNA delivery of CD64-CAR2, hCD16, CD64-CD16, or hnCD16, relative to cells without a construct (WT), and summarized in FIG. 8A.

[0037] FIG. 9A - FIG. 9C illustrate that knock-in (KI) of CD64-CAR5 (FIG. 9A) or CD64- CAR6 (FIG. 9B) into iNK cells resulted in enhanced ADCC, relative to the parental iNK cells (P5C7) (FIG. 9C) upon incubation with BT474 spheroids expressing mKate2 target cells (E:T 1 : 1) without or with 0.0001 pg/mL, 0.010 pg/mL, or 10 pg/mL trastuzumab, or rituximab 10 pg/mL.

[0038] FIG. 10A - FIG. 10C illustrate that KI of CD64-CAR5 (FIG. 10A) or CD64-CAR6 (FIG. 10B) into iNK cells resulted in enhanced ADCC following two rounds of expansion and 1 : 1 sAPC stimulation, relative to the parental iNK cells (P5C7) (FIG. 10C) upon incubation with BT474 spheroids expressing mKate2 target cells (E:T 2.5:1) without or with 0.0001 pg/mL, 0.010 pg/mL, or 10 pg/mL trastuzumab, or rituximab 10 pg/mL.

[0039] FIG. 11A - FIG. 11C illustrate that KI of CD64-CAR5 (FIG. 11 A) or CD64-CAR6 (FIG. 1 IB) into iNK cells resulted in enhanced ADCC following two rounds of expansion and 1 : 1 sAPC stimulation, relative to the parental iNK cells (P5C7) (FIG. 11C) upon incubation with BT474 spheroids expressing mKate2 target cells (E:T 1 : 1) without or with 0.0001 pg/mL, 0.010 pg/mL, or 10 pg/mL trastuzumab, or rituximab 10 pg/mL.

[0040] FIG. 12A - FIG. 12C illustrate that serum IgG (0, 2, 4, or 8 mg/mL) does not affect baseline killing in iNKs with knock-in (KI) of CD64-CAR5 (FIG. 12A) or CD64-CAR6 (FIG. 12B), relative to the parental iNK cells (P5C7) (FIG. 12C).

[0041] FIG. 13A - FIG. 13C illustrate that serum IgG (0, 2, 4, or 8 mg/mL) delays but does not inhibit ADCC mediated killing (E:T 2.5: 1) in iNKs with knock-in (KI) of CD64-CAR5 (FIG. 13 A) or CD64-CAR6 (FIG. 13B), relative to the parental iNK cells (P5C7) (FIG. 13C). DETAILED DESCRIPTION

[0042] In some aspects, the present disclosure provides chimeric receptors comprising an extracellular domain comprising a polypeptide of an IgG Fc receptor. In some embodiments, the present disclosure provides immune effector cells (e.g., NK cells) expressing a chimeric receptor described herein. In some embodiments, the present disclosure provides methods of using immune effector cells expressing a chimeric receptor described herein, for example, in treating cancer in a subject in need thereof.

[0043] Without wishing to be bound by theory, the chimeric receptors described herein induce or enhanced antibody-dependent cellular cytotoxicity (ADCC) of NK cells, optionally NK cells expressing a chimeric antigen receptor.

Chimeric Receptors

[0044] In some embodiments, the disclosure provides a chimeric receptor as described herein. In some embodiments, the chimeric receptor comprises an extracellular domain. In some embodiments, the extracellular domain comprises a polypeptide of an IgG Fc receptor. In some embodiments, the chimeric receptor comprises a transmembrane domain. In some embodiments, the chimeric receptor comprises a cytoplasmic domain. In some embodiments, the cytoplasmic domain comprises one or more signaling domains. In some embodiments, the cytoplasmic domain comprises a TIR signaling domain.

[0045] In some embodiments, the chimeric receptor described herein comprises from N- terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a transmembrane domain; and (iii) a cytoplasmic domain comprising one or more signaling domains. In some embodiments, the chimeric receptor described herein comprises from N-terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a transmembrane domain; and (iii) a cytoplasmic domain comprising a TIR signaling domain.

[0046] In some embodiments, the chimeric receptor described herein comprises from N- terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a transmembrane domain; (iii) a first linker; and (iv) a cytoplasmic domain comprising one or more signaling domains. In some embodiments, the chimeric receptor described herein comprises from N-terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a transmembrane domain; (iii) a first linker; and (iv) a cytoplasmic domain comprising two or more signaling domains operably linked by a second linker. In some embodiments, the chimeric receptor described herein comprises from N- terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a transmembrane domain; (iii) a first linker; and (iv) a cytoplasmic domain comprising a TIR signaling domain. In some embodiments, the chimeric receptor described herein comprises from N-terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a transmembrane domain; (iii) a first linker; and (iv) a cytoplasmic domain comprising a TIR signaling domain operably linked to an intracellular signaling domain via a second linker.

[0047] In some embodiments, the chimeric receptor described herein comprises from N- terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a transmembrane domain; (iii) a first linker; (iv) a first intracellular signaling domain; (v) a second linker; and (vi) a second intracellular signaling domain. In some embodiments, the chimeric receptor described herein comprises from N-terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a transmembrane domain; (iii) a first linker; (iv) a first intracellular signaling domain comprising a TIR signaling domain; (v) a second linker; and (vi) a second intracellular signaling domain.

[0048] In some embodiments, the chimeric receptor described herein comprises from N- terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a hinge domain; (iii) a transmembrane domain; and (iv) a cytoplasmic domain comprising one or more signaling domains. In some embodiments, the chimeric receptor described herein comprises from N-terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a hinge domain; (iii) a transmembrane domain; and (iv) a cytoplasmic domain comprising a TIR signaling domain.

[0049] In some embodiments, the chimeric receptor described herein comprises from N- terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a hinge domain; (iii) a transmembrane domain; (iv) a first linker; and (v) a cytoplasmic domain comprising one or more signaling domains. In some embodiments, the chimeric receptor described herein comprises from N-terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a hinge domain; (iii) a transmembrane domain; (iv) a first linker; and (v) a cytoplasmic domain comprising two or more signaling domains operably linked by a second linker. In some embodiments, the chimeric receptor described herein comprises from N-terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a hinge domain; (iii) a transmembrane domain; (iv) a first linker; and (v) a cytoplasmic domain comprising a TIR signaling domain. In some embodiments, the chimeric receptor described herein comprises from N-terminus to C- terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a hinge domain; (iii) a transmembrane domain; (iv) a first linker; and (v) a cytoplasmic domain comprising a TIR signaling domain operably linked to an intracellular signaling domain via a second linker.

[0050] In some embodiments, the chimeric receptor described herein comprises from N- terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a hinge domain; (iii) a transmembrane domain; (iv) a first linker; (v) a first intracellular signaling domain; (vi) a second linker; and (vii) a second intracellular signaling domain. In some embodiments, the chimeric receptor described herein comprises from N- terminus to C-terminus: (i) an extracellular domain comprising a polypeptide of an IgG Fc receptor; (ii) a hinge domain; (iii) a transmembrane domain; (iv) a first linker; (v) a first intracellular signaling domain comprising a TIR signaling domain; (vi) a second linker; and (vii) a second intracellular signaling domain.

Extracellular Domain - IgG Fc Receptor

[0051] In some embodiments, the chimeric receptors described herein comprise a polypeptide derived from an IgG Fc receptor. Immunoglobulin (Ig) Fc receptors (FcRs) are membrane molecules expressed by hematopoietic cells that recognize the Fc region of various immunoglobulin classes and subclasses. Antibody dependent cellular cytotoxicity (ADCC) is one of the major cytotoxic mechanisms employed by FcyR-expressing effector cells to eliminate tumor cells. In some embodiments, the chimeric receptors described herein comprising a polypeptide derived from an IgG Fc receptor induce or enhance ADCC of a cell relative to a cell lacking the chimeric receptor.

[0052] In some embodiments, a polypeptide derived from an IgG Fc receptor is the ectodomain (i.e., extracellular domain) of the receptor. In some embodiments, the polypeptide is the full ectodomain relative to a wild-type IgG Fc receptor. In some embodiments, the polypeptide is a fragment of the ectodomain relative to a wild-type IgG Fc receptor. In some embodiments, a fragment of the ectodomain of an IgG Fc receptor is binding fragment that retains binding to the Fc region of IgG. In some embodiments, the binding fragment comprises the Fc recognition domain of the IgG Fc receptor. In some embodiments, the binding fragment has the same binding affinity as the full ectodomain. In some embodiments, the polypeptide comprises the ectodomain or binding fragment thereof of the IgG Fc receptor.

[0053] In some embodiments, the IgG Fc receptor is selected from CD32 (c.g., CD32a, CD32b, CD32c) and CD64. In some embodiments, the IgG Fc receptor is CD32. In some embodiments, the IgG Fc receptor is CD32a. In some embodiments, the IgG Fc receptor is CD32b. In some embodiments, the IgG Fc receptor is CD32c. In some embodiments, the IgG Fc receptor is CD 64.

CD64

[0054] In some embodiments, a chimeric receptor described herein comprises an extracellular domain comprising an ectodomain or binding fragment thereof of CD64. CD64 is a high affinity Fc receptor expressed on monocytes and macrophages, not natural killer cells.

[0055] In some embodiments, a chimeric receptor as described herein comprises an extracellular domain comprising the Fc recognition domain of CD64.

[0056] In some embodiments, the extracellular domain of a chimeric receptor comprises an amino acid sequence set forth in SEQ ID NO: 38. In some embodiments, the extracellular domain of a chimeric receptor consists an amino acid sequence set forth in SEQ ID NO: 38. In some embodiments, the extracellular domain of a chimeric receptor comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 38.

[0057] In some embodiments, the extracellular domain of a chimeric receptor is encoded by the nucleotide sequence set forth in SEQ ID NO: 39. In some embodiments, the extracellular domain of a chimeric receptor is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 39. CD32

[0058] In some embodiments, a chimeric receptor described herein comprises an extracellular domain comprising an ectodomain or binding fragment thereof of the CD32 family. The CD32 family consists of CD32a, CD32b and CD32c. The CD32 receptor are low affinity Fc receptors. CD32a and CD32b have opposition cellular functions as CD32a is an activate-type Fc receptor whereas CD32b is an immune checkpoint that modulates the action of activating-type Fc receptors. The CD32 receptor family is expressed on B lymphocytes, macrophages and monocytes.

[0059] In some embodiments, a chimeric receptor as described herein comprises an extracellular domain comprising the Fc recognition domain of CD32a. In some embodiments, a chimeric receptor as described herein comprises an extracellular domain comprising the Fc recognition domain of CD32b. In some embodiments, a chimeric receptor as described herein comprises an extracellular domain comprising the Fc recognition domain of CD32c.

CD16

[0060] In some embodiments, a chimeric receptor described herein comprises an extracellular domain comprising an ectodomain or binding fragment thereof of CD 16. In some embodiments, a chimeric receptor as described herein comprises an extracellular domain comprising the Fc recognition domain of CD 16. In certain embodiments, the chimeric receptor described herein comprises an extracellular domain comprising an ectodomain or binding fragment thereof of a variant of CD 16 (e.g., high-affinity noncl eavable CD 16a (hnCD16), or high-affinity CD16a (hCD16)) (see, e.g., U.S. Patent No. 11,370,825, the disclosure of which is incorporated by reference herein in its entirety). In specific embodiments, the chimeric receptor described herein comprises an extracellular domain comprising an ectodomain or binding fragment thereof of hnCD16. In specific embodiments, the chimeric receptor described herein comprises an extracellular domain comprising an ectodomain or binding fragment thereof of hCD16.

[0061] In some embodiments, the extracellular domain of a chimeric receptor comprises an amino acid sequence set forth in SEQ ID NO: 160. In some embodiments, the extracellular domain of a chimeric receptor consists an amino acid sequence set forth in SEQ ID NO: 160. In some embodiments, the extracellular domain of a chimeric receptor comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 160. In some embodiments, the extracellular domain of a chimeric receptor comprises an amino acid sequence set forth in SEQ ID NO: 162. In some embodiments, the extracellular domain of a chimeric receptor consists an amino acid sequence set forth in SEQ ID NO: 162. In some embodiments, the extracellular domain of a chimeric receptor comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 162. In some embodiments, the extracellular domain of a chimeric receptor comprises an amino acid sequence set forth in SEQ ID NO: 163. In some embodiments, the extracellular domain of a chimeric receptor consists an amino acid sequence set forth in SEQ ID NO: 163. In some embodiments, the extracellular domain of a chimeric receptor comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 163.

[0062] In some embodiments, the extracellular domain of a chimeric receptor is encoded by the nucleotide sequence set forth in SEQ ID NO: 161. In some embodiments, the extracellular domain of a chimeric receptor is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 161. In some embodiments, the extracellular domain of a chimeric receptor is encoded by the nucleotide sequence set forth in SEQ ID NO: 164. In some embodiments, the extracellular domain of a chimeric receptor is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 164. In some embodiments, the extracellular domain of a chimeric receptor is encoded by the nucleotide sequence set forth in SEQ ID NO: 165. In some embodiments, the extracellular domain of a chimeric receptor is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 165.

Transmembrane Domain

[0063] In some embodiments, the chimeric receptors described herein comprise a transmembrane domain. In some embodiments, the transmembrane domain is operably linked to the extracellular domain with or without a linker. In some embodiments, the transmembrane domain is operably linked to the extracellular domain via a hinge domain as described herein. In some embodiments, the transmembrane domain is a naturally occurring transmembrane domain derived from a protein. In some embodiments, the transmembrane domain is a synthetic transmembrane domain. In some embodiments, the transmembrane domain comprises a full transmembrane domain of a polypeptide. In some embodiments, the transmembrane domain comprises a fragment of a transmembrane domain of a polypeptide.

[0064] In some embodiments, the transmembrane domain is a transmembrane domain of CD28, NKG2D, CD64, CD32a, CD32c, 2B4, CD8, CD4, CD3, NTB-A, DNAM1, IL-2R beta, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, IL-1R or IL-18R. In some embodiments, the transmembrane domain is a transmembrane domain of CD28, CD64, TLR2 or NKG2D. In some embodiments, the transmembrane domain is a transmembrane domain of CD28, CD64, TLR2, or NKG2D. In some embodiments, the transmembrane domain does not comprise a transmembrane domain of CD 16.

[0065] In some embodiments, the transmembrane domain is a transmembrane domain of CD28. In some embodiments, the transmembrane domain is a fragment of a CD28 transmembrane domain. In some embodiments, a CD28 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 23. In some embodiments, a CD28 transmembrane domain consists of the amino acid sequence set forth in SEQ ID NO: 23. In some embodiments, a CD28 transmembrane domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 23.

[0066] In some embodiments, a CD28 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 24. In some embodiments, a CD28 transmembrane domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 24.

[0067] In some embodiments, the transmembrane domain is a transmembrane domain of CD64. In some embodiments, the transmembrane domain is a fragment of a CD64 transmembrane domain. In some embodiments, a CD64 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, a CD64 transmembrane domain consists of the amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, a CD64 transmembrane domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 33.

[0068] In some embodiments, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34 or SEQ ID NO: 35. In some embodiments, a CD64 transmembrane domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 34 or SEQ ID NO: 35

[0069] In some embodiments, the transmembrane domain is a transmembrane domain of TLR2. In some embodiments, the transmembrane domain is a fragment of a TLR2 transmembrane domain. In some embodiments, a TLR2 transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 31. In some embodiments, a TLR2 transmembrane domain consists of the amino acid sequence set forth in SEQ ID NO: 31. In some embodiments, a TLR2 transmembrane domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 31.

[0070] In some embodiments, a TLR2 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 41. In some embodiments, a TLR2 transmembrane domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 32.

[0071] In some embodiments, the transmembrane domain is a transmembrane domain of NKG2D. In some embodiments, the transmembrane domain is a fragment of a NKG2D transmembrane domain. In some embodiments, the NKG2D transmembrane domain is in reverse orientation. As described herein, an NKG2D transmembrane domain in reverse orientation refers to the C-terminus of the NKG2D transmembrane domain being operably linked C-terminus of the extracellular domain, linker, or hinge domain as described herein. In some embodiments, an NKG2D transmembrane domain comprises the amino acid sequence set forth in SEQ ID NO: 36. In some embodiments, an NKG2D transmembrane domain consists of the amino acid sequence set forth in SEQ ID NO: 36. In some embodiments, an NKG2D transmembrane domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 36.

[0072] In some embodiments, an NKG2D transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 37. In some embodiments, an NKG2D transmembrane domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 37. Cytoplasmic Domain

[0073] In some embodiments, the chimeric receptors described herein comprise a cytoplasmic domain. In some embodiments, the cytoplasmic domain is operably linked to the transmembrane domain with or without a linker. In some embodiments, the cytoplasmic domain is operably linked to the transmembrane domain via a linker (e.g., a Gly-Ser linker). In some embodiments, the cytoplasmic domain comprises a naturally occurring signaling domain derived from a protein. In some embodiments, the cytoplasmic domain comprises a synthetic signaling domain. In some embodiments, the cytoplasmic domain comprises a full signaling domain of a polypeptide. In some embodiments, the cytoplasmic domain comprises a fragment of a signaling domain of a polypeptide. In some embodiments, the cytoplasmic domain comprises one or more signaling domains or active fragments thereof. In some embodiments, the cytoplasmic domain comprises one or more signaling domains. In some embodiments, the cytoplasmic domain comprises two or more signaling domains operably linked to each other without a linker. In some embodiments, the cytoplasmic domain comprises two or more signaling domains operably linked to each other with a linker.

[0074] In some embodiments, the cytoplasmic domain comprises a TIR signaling domain. In some embodiments, the cytoplasmic domain comprises a signaling domain of a TIR polypeptide. In some embodiments, the cytoplasmic domain comprises a fragment of a signaling domain of a TIR polypeptide. In some embodiments, the cytoplasmic domain comprises a TIR signaling domain operably linked to an intracellular signaling domain. In some embodiments, the cytoplasmic domain comprises a TIR signaling domain operably linked to an intracellular signaling domain via a linker. In some embodiments, the cytoplasmic domain comprises a TIR signaling domain operably linked to an intracellular signaling domain without a linker.

TIR Signaling Domain

[0075] In some embodiments, a chimeric receptor described herein comprises a Toll/interleukin-1 receptor (TIR) signaling domain.

[0076] In some embodiments, the TIR signaling domain is a signaling domain of a TLR polypeptide. In some embodiments, the TIR signaling domain is an active fragment of a signaling domain of a TLR polypeptide. In some embodiments, the TIR signaling domain is a signaling domain of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 or TLR10. In some embodiments, the TIR signaling domain is an active fragment of a signaling domain of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 or TLR10.

[0077] In some embodiments, the TIR signaling domain is a TLR2 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR2 signaling domain. In some embodiments, the TLR2 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 25. In some embodiments, the TLR2 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 25. In some embodiments, the TLR2 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 25. In some embodiments, the TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26. In some embodiments, the TLR2 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 26.

[0078] In some embodiments, the TIR signaling domain is a TLR1 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR1 signaling domain. In some embodiments, the TLR1 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 118. In some embodiments, the TLR1 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 118. In some embodiments, the TLR1 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 118. In some embodiments, the TLR1 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 119. In some embodiments, the TLR1 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 119.

[0079] In some embodiments, the TIR signaling domain is a TLR3 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR3 signaling domain. In some embodiments, the TLR3 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 120. In some embodiments, the TLR3 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 120. In some embodiments, the TLR3 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 120. In some embodiments, the TLR3 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 121 . In some embodiments, the TLR3 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 121.

[0080] In some embodiments, the TIR signaling domain is a TLR4 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR4 signaling domain. In some embodiments, the TLR4 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 122. In some embodiments, the TLR4 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 122. In some embodiments, the TLR4 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 122. In some embodiments, the TLR4 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 123. In some embodiments, the TLR4 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 123.

[0081] In some embodiments, the TIR signaling domain is a TLR5 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR5 signaling domain. In some embodiments, the TLR5 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 124. In some embodiments, the TLR5 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 124. In some embodiments, the TLR5 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 124. In some embodiments, the TLR5 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 125. In some embodiments, the TLR5 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 125.

[0082] In some embodiments, the TIR signaling domain is a TLR6 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR6 signaling domain. In some embodiments, the TLR6 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 126. In some embodiments, the TLR6 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 126. In some embodiments, the TLR6 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 126. In some embodiments, the TLR6 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 127. In some embodiments, the TLR6 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 127.

[0083] In some embodiments, the TIR signaling domain is a TLR7 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR7 signaling domain. In some embodiments, the TLR7 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 128. In some embodiments, the TLR7 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 128. In some embodiments, the TLR7 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 128. In some embodiments, the TLR7 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 129. In some embodiments, the TLR7 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 129.

[0084] In some embodiments, the TIR signaling domain is a TLR8 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR8 signaling domain. In some embodiments, the TLR8 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 130. In some embodiments, the TLR8 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 130. In some embodiments, the TLR8 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 130. In some embodiments, the TLR8 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 131. In some embodiments, the TLR8 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 131.

[0085] In some embodiments, the TIR signaling domain is a TLR9 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR9 signaling domain. In some embodiments, the TLR9 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 132. In some embodiments, the TLR9 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 132. In some embodiments, the TLR9 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 132. In some embodiments, the TLR9 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 133. In some embodiments, the TLR9 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 133.

[0086] In some embodiments, the TIR signaling domain is a TLR10 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of a TLR10 signaling domain. In some embodiments, the TLR10 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 134. In some embodiments, the TLR10 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 134. In some embodiments, the TLR10 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 134. In some embodiments, the TLR10 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 135. In some embodiments, the TLR10 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 135.

[0087] In some embodiments, the TIR signaling domain is a signaling domain of IL-1R. In some embodiments, the TIR signaling domain is an active fragment of a signaling domain of IL- 1R. In some embodiments, the TIR signaling domain is a signaling domain of IL-1R, IL-18R, IL-1R4, IL-1R6, IL-1R3, IL-1R7, IL-1R8, IL-1R9, or IL-1R10. In some embodiments, the TIR signaling domain is an active fragment of a signaling domain of IL-1R, IL-18R, IL-1R4, IL-1R6, IL-1R3, IL-1R7, IL-1R8, IL-1R9, or IL-1R10.

[0088] In some embodiments, the TIR signaling domain is an IL-1R signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-1R signaling domain. In some embodiments, the IL-1R signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 136. In some embodiments, the IL-1R signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 136. In some embodiments, the IL-1R signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 136. In some embodiments, the IL- 1R signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 137. In some embodiments, the IL-1R signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 137.

[0089] In some embodiments, the TIR signaling domain is an IL-18R signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-18R signaling domain. In some embodiments, the IL-18R signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 138. In some embodiments, the IL-18R signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 138. In some embodiments, the IL- 18R signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 138. In some embodiments, the IL-18R signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 139. In some embodiments, the IL-18R signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 139.

[0090] In some embodiments, the TIR signaling domain is an IL-1R4 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-1R4 signaling domain. In some embodiments, the IL-1R4 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 140. In some embodiments, the IL-1R4 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 140. In some embodiments, the IL-1R4 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 140. In some embodiments, the IL- 1R4 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 141. In some embodiments, the IL-1R4 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 141.

[0091] In some embodiments, the TIR signaling domain is an IL-1R6 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-1R6 signaling domain. In some embodiments, the IL-1R6 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 142. In some embodiments, the IL-1R6 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 142. In some embodiments, the IL-1R6 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 142. In some embodiments, the IL- 1R6 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 143. In some embodiments, the IL-1R6 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 143.

[0092] In some embodiments, the TIR signaling domain is an IL-1R3 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-1R3 signaling domain. In some embodiments, the IL-1R3 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the IL-1R3 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the IL-1R3 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 144. In some embodiments, the IL- 1R3 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 145. In some embodiments, the IL-1R3 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 145.

[0093] In some embodiments, the TIR signaling domain is an IL-1R7 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-1R7 signaling domain. In some embodiments, the IL-1R7 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 146. In some embodiments, the IL-1R7 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 146. In some embodiments, the IL-1R7 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 146. In some embodiments, the IL- 1R7 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 147. In some embodiments, the IL-1R7 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 147.

[0094] In some embodiments, the TIR signaling domain is an IL-1R8 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-1R8 signaling domain. In some embodiments, the IL-1R8 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 148. In some embodiments, the IL-1R8 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 148. In some embodiments, the IL-1R8 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 148. In some embodiments, the IL- 1R8 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 149. In some embodiments, the IL-1R8 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 149.

[0095] In some embodiments, the TIR signaling domain is an IL-1R9 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-1R9 signaling domain. In some embodiments, the IL-1R9 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 150. In some embodiments, the IL-1R9 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 150. In some embodiments, the IL-1R9 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 150. In some embodiments, the IL- 1R9 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 151. In some embodiments, the IL-1R9 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 151.

[0096] In some embodiments, the TIR signaling domain is an IL-1R10 signaling domain. In some embodiments, the TIR signaling domain is an active fragment of an IL-1R10 signaling domain. In some embodiments, the IL-1R10 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 152. In some embodiments, the IL-1R10 signaling domain consists of the amino acid sequence set forth in SEQ ID NO: 152. In some embodiments, the IL- 1R10 signaling domain comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 152. In some embodiments, the IL-1R10 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 153. In some embodiments, the IL-1R10 signaling domain is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 153. Intracellular Signaling Domain

[0097] In some embodiments, a chimeric receptor described herein comprises an intracellular signaling domain. In some embodiments, the intracellular signaling domain is operably linked to the TIR signaling domain with a linker. In some embodiments, the intracellular signaling domain is operably linked to the TIR signaling domain without a linker. In some embodiments, the N- terminus of the intracellular signaling domain is operably linked to the C-terminus of the TIR signaling domain. In some embodiments, the C-terminus of the intracellular signaling domain is operably linked to the N-terminus of the TIR signaling domain.

[0098] In some embodiments, the intracellular signaling domain is a signaling domain know to those of skill in the art and useful in chimeric receptors (e.g., chimeric antigen receptors). In some embodiments, the intracellular signaling domain does not comprise an intracellular signaling domain of CD 16.

[0099] In some embodiments, the intracellular signaling domain is a 2B4 signaling domain. In some embodiments, the 2B4 signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 50. In some embodiments, the 2B4 signaling domain consists of amino acid sequence set forth in SEQ ID NO: 50. In some embodiments, the 2B4 signaling domain comprises an amino acid sequence 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 50. In some embodiments, the 2B4 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 51. In some embodiments, the 2B4 signaling domain is encoded by a nucleotide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 51.

[00100] In some embodiments, the intracellular signaling domain is CD3zeta signaling domain. In some embodiments, the CD3zeta signaling domain comprises the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the CD3zeta signaling domain consists of amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the CD3zeta signaling domain comprises an amino acid sequence 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 27. In some embodiments, the CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, the CD3zeta signaling domain is encoded by a nucleotide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. Linkers

[00101] In some embodiments, a chimeric receptor described herein comprises one or more linkers between the components of the receptors. In some embodiments, a chimeric receptor described herein comprises a linker between the extracellular domain and the transmembrane domain. In some embodiments, a chimeric receptor described herein comprises a linker between the transmembrane domain and the cytoplasmic domain. In some embodiments, a chimeric receptor described herein comprises a linker between two or more intracellular signaling domains of the cytoplasmic domain.

[00102] As used herein, the terms "linked," "fused", “operably linked” or "fusion" are used interchangeably. These terms refer to the joining together of two or more elements or components or domains, by whatever means including chemical conjugation or recombinant means. Methods of chemical conjugation (e.g., using heterobifunctional crosslinking agents) are known in the art.

Hinge Domains

[00103] In some embodiments, the extracellular domain and the transmembrane domain of a chimeric receptor described herein are linked by a hinge domain. The "spacer" or "hinge" region, is the connecting sequence between the ectodomain and the transmembrane domain.

[00104] In some embodiments, the hinge domain is derived from a CD8alpha polypeptide. In some embodiments, the CD8alpha hinge comprises the amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the CD8alpha hinge consists of amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the CD8alpha hinge comprises an amino acid sequence 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 144. In some embodiments, the CD8alpha hinge is encoded by the nucleotide sequence set forth in SEQ ID NO: 145. In some embodiments, CD8alpha hinge is encoded by a nucleotide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 145.

[00105] In some embodiments, the hinge domain is derived from a CD28 polypeptide. In some embodiments, the CD28 hinge comprises the amino acid sequence set forth in SEQ ID NO: 146. In some embodiments, the CD28 hinge consists of amino acid sequence set forth in SEQ ID NO: 146. In some embodiments, the CD28 hinge comprises an amino acid sequence 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 146. In some embodiments, the CD28 hinge is encoded by the nucleotide sequence set forth in SEQ ID NO: 147. In some embodiments, CD28 hinge is encoded by a nucleotide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 147. [00106] In some embodiments, the hinge domain is derived from a IgG4 polypeptide. In some embodiments, the IgG4 hinge comprises the amino acid sequence set forth in SEQ ID NO: 148. In some embodiments, the IgG4 hinge consists of amino acid sequence set forth in SEQ ID NO:

148. In some embodiments, the IgG4 hinge comprises an amino acid sequence 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 148. In some embodiments, the IgG4 hinge is encoded by the nucleotide sequence set forth in SEQ ID NO:

149. In some embodiments, IgG4 hinge is encoded by a nucleotide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 149.

Gly-Ser Linkers

[00107] Linkers suitable for joining polypeptide sequences are known to those of skill in the art. Exemplary linkers include gly-ser polypeptide linkers, glycine -proline polypeptide linkers, and proline- alanine polypeptide linkers. In certain embodiments, the linker is a gly-ser polypeptide linker, i.e., a peptide that consists of glycine and serine residues.

[00108] As used herein, the term "gly-ser linker" refers to a peptide that consists of glycine and serine residues. An exemplary gly-ser polypeptide linker comprises the amino acid sequence Ser(Gly4Ser)n. In some embodiments, n=l . In certain embodiments, n=2. In certain embodiments, n=3, i.e., Ser(Gly4Ser)3. In some embodiments, n=4, i.e., Ser(Gly4Ser)4. In certain embodiments, n=5. In certain embodiments, n=6. In some embodiments, n=7. In some embodiments, n=8. In some embodiments, n=9. In certain embodiments, n=10. Another exemplary gly-ser polypeptide linker comprises the amino acid sequence (Gly4Ser)n. In some embodiments, n=l. In certain embodiments, n=2. In certain embodiments, n=3. In some embodiments, n=4. In certain embodiments, n=5. In certain embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises the amino acid sequence (GlysSerjn. In some embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3. In some embodiments, n=4. In some embodiments, n=5. In some embodiments, n=6. Exemplary gly-ser polypeptide linkers comprise the amino acid sequence Ser(Gly4Ser)n. In some embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3, i.e., Ser(Gly4Ser)3. In some embodiments, n=4, i.e., Ser(Gly4Ser)4. In some embodiments, n=5. In certain embodiments, n=6. In some embodiments, n=7. In some embodiments, n=8. In certain embodiments, n=9. In some embodiments, n=10. Another exemplary gly-ser polypeptide linker comprises the amino acid sequence Ser(Gly4Ser)n. In certain embodiments, n=l. In some embodiments, n=2. In some embodiments, n=3. In certain embodiments, n=4. In some embodiments, n=5. certain embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises (Gly4Ser)n. In some embodiments, n=l. In some embodiments, n=2. In certain embodiments, n=3. In some embodiments, n=4. In some embodiments, n=5. In certain embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises (GlysSer)n. In some embodiments, n=l. In some embodiments, n=2. In certain embodiments, n=3. In certain embodiments, n=4. In some embodiments, n=5. In some embodiments n=6.

[00109] In some embodiments, a chimeric receptor described herein comprises a gly-ser linker as set forth in SEQ ID NO: 9. In some embodiments, the gly-ser linker is encoded by the nucleotide sequence of SEQ ID NO: 10. In some embodiments, a chimeric receptor described herein comprises a gly-ser linker as set forth in SEQ ID NO: 11. In some embodiments, the gly- ser linker is encoded by the nucleotide sequence of SEQ ID NO: 12. In some embodiments, a chimeric receptor described herein comprises a gly-ser linker as set forth in SEQ ID NO: 13. In some embodiments, the gly-ser linker is encoded by the nucleotide sequence of SEQ ID NO: 14. In some embodiments, a chimeric receptor described herein comprises a gly-ser linker as set forth in SEQ ID NO: 15. In some embodiments, the gly-ser linker is encoded by the nucleotide sequence of SEQ ID NO: 16.

Exemplary Chimeric Receptors

[00110] In some embodiments, a chimeric receptor described herein comprises:

(iii) a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain; or (iv) a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain.

[001111 In some embodiments, a chimeric receptor described herein comprises:

(i) SEQ ID NO: 106 or SEQ ID NO: 107;

(ii) SEQ ID NO: 105;

(ii) SEQ ID NO: 104; or

(iv) SEQ ID NO: 102 or SEQ ID NO: 103.

[00112] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a CD64 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 33, and a CD64 intracellular domain comprising the amino acid sequence set forth in SEQ ID NO: 44. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34, and a CD64 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 45. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53.

[00113] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a gly-ser linker, a 2B4 signaling domain, a gly-ser linker, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a NKG2D transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 36, a 2B4 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 50, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a NKG2D transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 36, a gly-ser linker, a 2B4 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 50, a gly-ser linker, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a NKG2D transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 36, a gly- ser linker comprising the amino acid sequence set forth in SEQ ID NO: 11, a 2B4 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 52, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 13, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a NKG2D transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 37, a 2B4 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 51, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a NKG2D transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 37, a gly-ser linker, a 2B4 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 51, a gly-ser linker, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a NKG2D transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 37, a gly-ser linker is encoded by the nucleotide sequence set forth in SEQ ID NO: 12, a 2B4 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 51, a gly-ser linker is encoded by the nucleotide sequence in SEQ ID NO: 14, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 33. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57.

[00114] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 39, a CD64 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 33, a CD64 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 44, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 40, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34 or SEQ ID NO: 35, a CD64 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 45, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65.

[001151 In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 39, a CD64 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 33, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 40, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 69. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69. [00116] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 39, a CD64 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 33, a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 40, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34, a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73. [00117] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 39, a CD64 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 33, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C- terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 40, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77.

[00118] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a gly-ser linker, a TLR2 signaling domain, a gly-ser linker, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a NKG2D transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 36, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a NKG2D transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 36, a gly-ser linker, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a NKG2D transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 38, a gly- ser linker comprising the amino acid sequence set forth in SEQ ID NO: 11, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 13, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a NKG2D transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 36, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a NKG2D transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 36, a gly-ser linker, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a NKG2D transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 37, a gly-ser linker is encoded by the nucleotide sequence set forth in SEQ ID NO: 12, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker is encoded by the nucleotide sequence in SEQ ID NO: 14, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81. [00119] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a gly-ser linker, a TLR2 signaling domain, a gly-ser linker, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a CD64 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 33, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a CD64 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 33, a gly-ser linker, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a CD64 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 33, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 11, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 13, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34 or SEQ ID NO: 35, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34 or SEQ ID NO: 35, a gly-ser linker, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a CD64 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 34 or SEQ ID NO: 35, a gly-ser linker is encoded by the nucleotide sequence set forth in SEQ ID NO: 12, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker is encoded by the nucleotide sequence in SEQ ID NO: 14, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89.

[00120] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a gly-ser linker, a TLR2 signaling domain, a gly-ser linker, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a CD28 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 23, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a CD28 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 23, a gly-ser linker, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a CD28 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 23, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 11, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 13, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a CD28 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 24, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a CD28 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 24, a gly-ser linker, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a CD28 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 24, a gly-ser linker is encoded by the nucleotide sequence set forth in SEQ ID NO: 12, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker is encoded by the nucleotide sequence in SEQ ID NO: 14, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93. [00121] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a gly-ser linker, a TLR2 signaling domain, a gly-ser linker, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a TLR2 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 40, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a TLR2 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 40, a gly-ser linker, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a TLR2 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 40, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 11, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 13, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a TLR2 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 41, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a TLR2 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 32, a gly-ser linker, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a TLR2 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 41, a gly-ser linker is encoded by the nucleotide sequence set forth in SEQ ID NO: 12, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker is encoded by the nucleotide sequence in SEQ ID NO: 14, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97. [00122] In some embodiments, a chimeric receptor described herein comprises from N- terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP, a TLR2 signaling domain, a gly-ser linker, and a CD3zeta signaling domain. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a TLR2 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 40, a TLR2 MP comprising the amino acid sequence set forth in SEQ ID NO: 42, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a TLR2 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 40, a TLR2 MP comprising the amino acid sequence set forth in SEQ ID NO: 42, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain comprising the amino acid sequence set forth in SEQ ID NO: 38, a TLR2 transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO: 40, a TLR2 MP comprising the amino acid sequence set forth in SEQ ID NO: 42, a TLR2 signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 25, a gly-ser linker comprising the amino acid sequence set forth in SEQ ID NO: 13, and a CD3zeta signaling domain comprising the amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a TLR2 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 41, a TLR2 MP is encoded by the nucleotide sequence set forth in SEQ ID NO: 43, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a TLR2 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 41, a TLR2 MP is encoded by the nucleotide sequence set forth in SEQ ID NO: 43, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises from N-terminus to C-terminus: a CD64 ectodomain is encoded by the nucleotide sequence set forth in SEQ ID NO: 39, a TLR2 transmembrane domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 41, a TLR2 MP comprising the amino acid sequence set forth in SEQ ID NO: 43, a TLR2 signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 26, a gly-ser linker is encoded by the nucleotide sequence in SEQ ID NO: 14, and a CD3zeta signaling domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 28, SEQ ID NO: 31, or SEQ ID NO: 32. In some embodiments, a chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, a chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, a chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, a chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101. Chimeric Receptor Expressing Cells

[00123] In some embodiments, the disclosure provides a cell expressing a chimeric receptor described herein. In some embodiments, the disclosure provides a cell comprises a polynucleotide sequence encoding a chimeric receptor described herein.

Types of Cells

[00124] In some embodiments, the disclosure provides an immune effector cell expressing a chimeric receptor described herein. In some embodiments, the disclosure provides an immune effector cell comprising a polynucleotide sequence encoding a chimeric receptor described herein.

[00125] Immune effector cells suitable for expressing a chimeric receptor described herein includes, but is not limited to, natural killer (NK) cells and macrophage cells. In some embodiments, an immune effector cell, such as a Natural Killer cell, is derived from a stem cell. In some embodiments, the stem cell is a hematopoietic stem cell. In some embodiments, the stem cell is an induced pluripotent stem cell. In some embodiments, the cell is an iPSC-derived immune cell. In some embodiments, the cell is a peripheral blood cell derived immune cell. In some embodiments, the cell is a cord blood cell derived immune cell. In some embodiments, the cell is an embryonic stem cell derived immune cell. In some embodiments, a stem cell is engineered to express a chimeric receptor described herein and differentiated to an immune effector cell (e.g, natural killer cell). In some embodiments, the cell is an iPSC-derived NK cell. In some embodiments, the cell is a peripheral blood cell derived NK cell. In some embodiments, the cell is a cord blood cell derived NK cell. In some embodiments, the cell is an embryonic stem cell derived NK cell. In some embodiments, a stem cell is engineered to express a chimeric receptor described herein and differentiated to an NK cell (e.g., natural killer cell). In some embodiments, a stem cell derived NK cell is CD45+/CD56+ double-positive. In some embodiments, the immune cell is CD45+. In some embodiments, the immune cell is CD56+. In some embodiments the immune cell is CD45+, CD56+, or CD45+/CD56+. Illustrative methods for making and using engineered cells are provided in Int’l Pat. Appl. Nos. WO 2017100861 Al, WO 2018/075664 Al, WO 2019/213610 Al, WO 2019/217956 Al, and WO 2020/113029 A2, the disclosures of which are incorporated by reference herein in their entireties. Other Cell Modifications

[00126] In some embodiments, the cells suitable for expressing a chimeric receptor described herein comprise one or more genetic modifications. In some embodiments, the cells suitable for expressing a chimeric receptor described herein express one or more additional polypeptides on the surface.

Genetic Modifications

[00127] In some embodiments, a cell described herein comprises one or more mutations in a gene to downregulate expression of the gene. In some embodiments, a cell described herein comprises one or more mutations in a gene to upregulate expression of a gene. In some embodiments, a cell described herein is genetically engineered to knock-out or knock-in a gene. In some embodiments, a cell described herein is not genetically engineered to knock-out a gene. [00128] In some embodiments, a cell described herein comprises one or more mutations to downregulate expression of CISH. In some embodiments, a cell described herein is genetically engineered to knock-out a CISH gene. In some embodiments, a cell described herein comprises one or more inactivating mutations in a cytokine-inducible SH2-containing protein (CISH) gene. In some embodiments, a cell described herein comprises homozygous inactivating mutations in a cytokine-inducible SH2-containing protein (CISH) gene. In some embodiments, a cell described herein comprises heterozygous inactivating mutations in a cytokine-inducible SH2-containing protein (CISH) gene. In some embodiments, a cell described herein is CISH'⁷'. In some embodiments, a cell described herein is CISH^+/'. In some embodiments, a cell described herein comprises homozygous inactivating mutations of the transforming growth factor beta receptor 2 (TGFBR2) genes (e.g, TGFBR2 -/-). In some embodiments, a cell described herein does not comprise homozygous inactivating mutations of the transforming growth factor beta receptor 2 (TGFBR2) genes (e.g, TGFBR2 +/+). In some embodiments, a cell described herein comprises homozygous inactivating mutations of the beta-2-microglobulin (B2M) genes (e.g., B2M -/-). In some embodiments, a cell described herein comprises homozygous inactivating mutations of the class II major histocompatibility complex transactivator (CIITA) genes (e.g., CIITA -/-). In some embodiments, a cell described herein comprises homozygous inactivating mutations of the regulatory factor X (RFX) genes (e.g., RFX -/-). Methods for genetically engineering cells are known in the art and described herein. Surface Polypeptides

[00129] In some embodiments, a cell described herein expresses one or more polypeptide on the surface of the cell. In some embodiments, a cell described herein expresses one or more cytokines on the surface of the cell. In some embodiments, a cell described herein expresses an IL- 15 polypeptide on the surface of the cell. In some embodiments, a cell described herein comprises a polynucleotide sequence encoding an IL- 15 polypeptide. In some embodiments, a cell described herein expresses an IL- 18 polypeptide on the surface of the cell. In some embodiments, a cell described herein comprises a polynucleotide sequence encoding an IL-18 polypeptide.

[00130] IL- 15 polypeptides suitable for expression on the surface of a cell are known to those of skill in the art. For example, in some embodiments, an IL-15 polypeptide is a fusion protein comprising an IL- 15 polypeptide linked to an IL-15Roc polypeptide. In some embodiments, an IL-15 polypeptide is a fusion protein comprising an IL-15 polypeptide linked to an IL-15R sushi domain.

[00131] In some embodiments, an IL- 15 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, an IL-15 polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 17. In some embodiments, an IL-15 polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 18. In some embodiments, an IL- 15 polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 18.

[00132] In some embodiments, an IL-15Roc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 21. In some embodiments, an IL-15Roc polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 21. In some embodiments, an IL-15Roc polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 22. In some embodiments, an IL-15Ra polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 22.

[00133] In some embodiments, an IL- 15 fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, an IL-15 fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, an IL-15 fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, an IL-15 fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

Exemplary Modified Cells

[00134] Methods for making modified cells, such as progenitor cells or immune effector cells, are known to those of skill in the art. Methods for making cells expressing polypeptides, such as the chimeric receptors or fusion polypeptides described herein, are known in the art. Exemplary methods are described herein.

Progenitor Cells

[00135] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53.

[00136] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 55.

[00137] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the fusion polypeptide comprises the amino acid sequence set for in SEQ ID NO: 29. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00138] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL-15 and IL-15R, e.g., IL15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses an IL- 15 and IL-15R, e.g., IL- 15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the fusion polypeptide comprises the amino acid sequence set for in SEQ ID NO: 29. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00139] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57.

[00140] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57.

[00141] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57. In some embodiments, the IL-15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00142] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a fusion polypeptide (e.g, an IL- 15 and IL15R, for example, IL15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a membrane-bound IL 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example IL15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00143] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65.

[00144] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65.

[00145] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65. In some embodiments, the IL- 15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00146] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and coexpresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example, IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00147] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 69. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69. [00148] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 69. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69.

[00149] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 69. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00150] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example IL- 15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 69. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00151] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73.

[00152] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73.

[00153] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73. In some embodiments, the IL- 15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00154] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R fusion, for example IL-15Ralpha, polypeptide) and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00155] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77.

[00156] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77.

[00157] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00158] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL-15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses an IL-15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77. In some embodiments, the IL-15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00159] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81.

[00160] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81.

[00161] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81. In some embodiments, the IL- 15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00162] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and coexpresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses an IL-15 and IL-15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00163] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89.

[00164] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89.

[00165] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89. In some embodiments, the IL-15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00166] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and coexpresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00167] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93.

[00168] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93.

[00169] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93. In some embodiments, the IL- 15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00170] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL-15 and IL-15R fusion, e.g., IL-15Ralpha, polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and coexpresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses an IL-15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00171] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97.

[00172] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97.

[00173] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL-15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97. In some embodiments, the IL-15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00174] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g.. IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and coexpresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses an IL-15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00175] In some embodiments, a progenitor cell, such as a stem cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101.

[00176] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101. [00177] In some embodiments, the progenitor cell, such as a stem cell, co-expresses an IL-15 and IL15R fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30. [00178] In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the progenitor cell, such as a stem cell, is a CISH knockout cell and co-expresses an IL-15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

Immune Effector Cells

[00179] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53. [00180] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53.

[00181] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the fusion polypeptide comprises the amino acid sequence set for in SEQ ID NO: 29. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00182] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses an IL-15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD64 intracellular domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the fusion polypeptide comprises the amino acid sequence set for in SEQ ID NO: 29. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 52. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 53. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00183] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57.

[00184] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57.

[00185] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57. In some embodiments, the IL-15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00186] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and cell co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and cell co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example, IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a 2B4 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 57. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00187] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65.

[00188] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65.

[00189] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65. In some embodiments, the IL- 15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30. [00190] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and the cell co-expresses a membranebound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and the cell co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example, IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD64 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 65. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 65. In some embodiments, the IL- 15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30. [00191] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 69. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69. [00192] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 69. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69.

[00193] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ TD NO: 69. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00194] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a fusion polypeptide (e.g., an IL-15 and IL15R, for example, IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. . In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a fusion polypeptide (e.g., an IL-15 and IL15R, for example IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 68. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 69. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 69. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00195] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73.

[00196] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73.

[00197] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00198] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a fusion polypeptide (e.g., an IL-15 and TL15R, for example IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a fusion polypeptide (e.g., an IL- 15 and IL15R, for example IL-15Ralpha, fusion polypeptide) and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 73. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 73. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00199] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77.

[00200] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77.

[00201] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00202] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL-15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a CD3zeta signaling domain, a CD3zeta signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 76. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 77. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 77. In some embodiments, the IL-15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00203] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81.

[00204] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81.

[00205] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00206] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a NKG2D transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 80. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 81. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 81. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00207] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89.

[00208] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89.

[00209] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89. In some embodiments, the IL-15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00210] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g, IL- 15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses an IL-15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 88. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 89. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 89. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00211] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93.

[00212] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93.

[00213] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93. In some embodiments, the IL- 15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00214] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g., IL- 15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 92. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 93. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00215] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97. [00216] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97.

[00217] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97. In some embodiments, the IL-15 and IL- 15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00218] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses an IL- 15 and IL-15R, e.g, IL- 15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses an IL- 15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 97. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 97. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00219] In some embodiments, an immune effector cell, such as a Natural Killer cell, expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101.

[00220] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and expresses a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101.

[00221] In some embodiments, the immune effector cell, such as a Natural Killer cell, coexpresses an IL- 15 and IL15R fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101. In some embodiments, the IL-15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL- 15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

[00222] In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, comprises one or more inactivating mutations in CISH and co-expresses an IL-15 and IL-15R, e.g., IL-15Ralpha, fusion polypeptide and a chimeric receptor comprising from N- terminus to C-terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses a membrane-bound IL- 15 polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the immune effector cell, such as a Natural Killer cell, is a CISH knockout cell and co-expresses an IL- 15 and IL-15R, e.g., IL- 15Ralpha, fusion polypeptide and a chimeric receptor comprising from N-terminus to C- terminus: a CD64 ectodomain, a TLR2 transmembrane domain, a TLR2 MP , a TLR2 signaling domain, and a CD3zeta signaling domain. In some embodiments, the chimeric receptor described herein comprises the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 100. In some embodiments, the chimeric receptor described herein is ended by the nucleotide sequence set forth in SEQ ID NO: 101. In some embodiments, the chimeric receptor described herein is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 101. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the IL- 15 and IL-15R fusion polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 29. In some embodiments, the IL-15 and IL-15R fusion polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO: 30. In some embodiments, the IL- 15 and IL-15R fusion polypeptide is encoded by a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30.

Methods of Making Chimeric Receptors and Cells Expressing Chimeric Receptors

[00223] Methods for making chimeric receptors are known to those of skill in the art and include methods for making polypeptides. Exemplary methods are described herein. Methods for making cells expressing polypeptides, such as the chimeric receptors described herein, are known in the art. Exemplary methods are described herein.

Methods of Making Polypeptides

[00224] In some embodiments, the polypeptides described herein are made in transformed host cells using recombinant DNA techniques. To do so, a recombinant DNA molecule coding for the peptide is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences coding for the peptides could be excised from DNA using suitable restriction enzymes. Alternatively, the DNA molecule could be synthesized using chemical synthesis techniques, such as the phosphoramidate method. Also, a combination of these techniques could be used.

[00225] The methods of making polypeptides also include a vector capable of expressing the peptides in an appropriate host. The vector includes the DNA molecule that codes for the peptides operatively linked to appropriate expression control sequences. Methods of affecting this operative linking, either before or after the DNA molecule is inserted into the vector, are well known. Expression control sequences include promoters, activators, enhancers, operators, ribosomal nuclease domains, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the control of transcription or translation.

[00226] The resulting vector having the DNA molecule thereon is used to transform an appropriate host. This transformation may be performed using methods well known in the art. Any of a large number of available and well-known host cells may be suitable for use in the methods disclosed herein. The selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial hosts include bacteria (such as E. coli sp.), yeast (such as Saccharomyces sp.) and other fungi, insects, plants, mammalian (including human) cells in culture, or other hosts known in the art.

[00227] Next, the transformed host is cultured and purified. Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art. Finally, the peptides are purified from culture by methods well known in the art.

[00228] The polypeptides may also be made by synthetic methods. For example, solid phase synthesis techniques may be used. Suitable techniques are well known in the art, and include those described in Merrifield (1973), Chem. Polypeptides, pp. 335-61 (Katsoyannis and Panayotis eds.); Merrifield (1963), J. Am. Chem. Soc. 85: 2149; Davis et al. (1985), Biochem. Inti. 10: 394-414; Stewart and Young (1969), Solid Phase Peptide Synthesis; U.S. Pat. No. 3,941 ,763; Finn et al. (1976), The Proteins (3rd ed.) 2: 105-253; and Erickson et al. (1976), The Proteins (3rd ed.) 2: 257-527. Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides. Compounds that contain derivatized peptides or which contain non-peptide groups may be synthesized by well-known organic chemistry techniques. Other methods are of molecule expression/synthesis are generally known in the art to one of ordinary skill.

[00229] The nucleic acid molecules described above can be contained within a vector that is capable of directing their expression in, for example, a cell that has been transduced with the vector. Accordingly, in addition to polypeptide mutants, expression vectors containing a nucleic acid molecule encoding a mutant and cells transfected with these vectors are among the certain embodiments. Vectors suitable for use include T7-based vectors for use in bacteria (see, for example, Rosenberg et al., Gene 56: 125, 1987), the pMSXND expression vector for use in mammalian cells (Lee and Nathans, J. Biol. Chem. 263:3521 , 1988), and baculovirus-derived vectors (for example the expression vector pBacPAKS from Clontech, Palo Alto, Calif.) for use in insect cells.

[00230] The nucleic acid inserts, which encode the polypeptide of interest in such vectors, can be operably linked to a promoter, which is selected based on, for example, the cell type in which expression is sought. For example, a T7 promoter can be used in bacteria, a polyhedrin promoter can be used in insect cells, and a cytomegalovirus or metallothionein promoter can be used in mammalian cells. Also, in the case of higher eukaryotes, tissue-specific and cell type- specific promoters are widely available. These promoters are so named for their ability to direct expression of a nucleic acid molecule in a given tissue or cell type within the body. Skilled artisans are well aware of numerous promoters and other regulatory elements which can be used to direct expression of nucleic acids.

[00231] In addition to sequences that facilitate transcription of the inserted nucleic acid molecule, vectors can contain origins of replication, and other genes that encode a selectable marker. For example, the neomycin-resi stance (neo^r) gene imparts G418 resistance to cells in which it is expressed, and thus permits phenotypic selection of the transfected cells. Those of skill in the art can readily determine whether a given regulatory element or selectable marker is suitable for use in a particular experimental context.

[00232] Viral vectors that are suitable for use include, for example, retroviral, adenoviral, lentiviral, and adeno-associated vectors, herpes virus, simian virus 40 (SV 40), and bovine papilloma virus vectors (see, for example, Gluzman (Ed.), Eukaryotic Viral Vectors, CSH Laboratory Press, Cold Spring Harbor, N.Y.). Prokaryotic or eukaryotic cells that contain and express a nucleic acid molecule that encodes a polypeptide mutant are also suitable for use. A cell is a transfected cell, i.e., a cell into which a nucleic acid molecule, for example a nucleic acid molecule encoding a mutant polypeptide, has been introduced by means of recombinant DNA techniques. The progeny of such a cell are also considered suitable for use in the methods disclosed herein.

[00233] The precise components of the expression system are not critical. For example, a polypeptide mutant can be produced in a prokaryotic host, such as the bacterium E. coli, or in a eukaryotic host, such as an insect cell (e.g, an Sf21 cell), or mammalian cells (e.g, COS cells, NIH 3T3 cells, or HeLa cells). These cells are available from many sources, including the American Type Culture Collection (Manassas, Va.). In selecting an expression system, it matters only that the components are compatible with one another. Artisans of ordinary skill are able to make such a determination. Furthermore, if guidance is required in selecting an expression system, skilled artisans may consult Ausubel et al. (Current Protocols in Molecular Biology, John Wiley and Sons, New York, N.Y., 1993) and Pouwels et al. (Cloning Vectors: A Laboratory Manual, 1985 Suppl. 1987).

[00234] The expressed polypeptides can be purified from the expression system using routine biochemical procedures, and can be used, e.g., conjugated to a lipid, as described herein.

Genetic Engineering

[00235] In some embodiments, a cell described herein is genetically engineered to express a chimeric receptor described herein. Genetic engineering can refer to transient expression or stable expression.

[00236] In some embodiments, an immune effector cell, such as a Natural Killer cell, (e.g, NK cell) is genetically modified with a chimeric receptor. For example, an immune effector cell (e.g, NK cell) is provided and a recombinant nucleic acid encoding a chimeric receptor is introduced into the effector cell (e.g., NK cell) to generate an engineered cell. In some embodiments, immune effector cells (e.g, NK cells) are derived from a subject and genetically modified with a chimeric receptor. In some embodiments, immune effector cells (e.g, NK cells) are not derived from the subject and are genetically modified with a chimeric receptor. For example, in some embodiments, immune effector cells (e.g, NK cells) are allogeneic cells that have been engineered to be used as an "off the shelf adoptive cell therapy, such as Universal Chimeric Antigen Receptor T cells (UCARTs), as developed by Cellectis. UCARTs are allogeneic CAR T cells that have been engineered to be used for treating the largest number of patients with a particular cancer type.

[00237] A variety of different methods known in the art can be used to introduce any of the nucleic acids or expression vectors disclosed herein into an immune effector cell (e.g., NK cell) or a pluripotent cell, which may be stably maintained by the cell and/or integrated into the genome of the cell. Non-limiting examples of methods for introducing nucleic acid into an immune effector cell (e.g., NK cell) include: lipofection, transfection (e.g., calcium phosphate transfection, transfection using highly branched organic compounds, transfection using cationic polymers, dendrimer-based transfection, optical transfection, particle-based transfection (e.g., nanoparticle transfection), or transfection using liposomes (e.g., cationic liposomes)), microinjection, electroporation, cell squeezing, sonoporation, protoplast fusion, impalefection, hydrodynamic delivery, gene gun, magnetofection, viral transfection, and nucleofection. Furthermore, the CRISPR/Cas9 genome editing technology known in the art can be used to introduce chimeric receptor nucleic acids into immune effector cell (e.g., NK cell) and/or to introduce other genetic modifications (e.g., as described below) into effector cells (e.g., T cells) to enhance CAR cell activity (for use of CRISPR/Cas9 technology in connection with CAR T cells, see e.g, US 9,890,393; US 9,855,297; US 2017/0175128; US 2016/0184362; US 2016/0272999; WO 2015/161276; WO 2014/191128; CN 106755088; CN 106591363; CN 106480097; CN 106399375; CN 104894068).

[00238] In some embodiments, the polynucleotide is knocked-in to the genome of an immune effector cell (e.g., NK cell) or a pluripotent cell. In some embodiments, the polynucleotide is knocked into a safe harbor locus (e.g., AAVS1). In some embodiments, the polynucleotide is knocked into an essential gene (see, e.g., WO 2021/22615).

Compositions of Chimeric Receptor Expressing Cells

[00239] In some embodiments, the disclosure provides a composition of a chimeric receptor expressing cell. In some embodiments, the disclosure provides a composition of a population of cells comprising one or more chimeric receptor expressing cells. In some embodiments, the disclosure provides a composition of a population of cells comprising a plurality of chimeric receptor expressing cells.

[00240] In some embodiments, the disclosure provides a pharmaceutical composition or formulation of a chimeric receptor expressing cell. In some embodiments, the disclosure provides a pharmaceutical composition or formulation of a population of cells comprising one or more chimeric receptor expressing cells. In some embodiments, the disclosure provides a pharmaceutical composition or formulation of a population of cells comprising a plurality of chimeric receptor expressing cells.

[00241] Formulations suitable for cell therapy are known to one of skill in the art. In some embodiments, the cells are formulated by first harvesting them from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier) in a treatment-effective amount. Suitable infusion medium can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized. The infusion medium can be supplemented with human serum albumin. [00242] The liquid pharmaceutical compositions, whether they be solutions, suspensions or other like form, may include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. An injectable pharmaceutical composition is preferably sterile.

[00243] Pharmaceutical compositions of the present disclosure may be administered in a manner appropriate to the disease to be treated (or prevented). The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages may be determined by clinical trials. Methods of Using Chimeric Receptor Expressing Cells

[00244] In some embodiments, the disclosure provides methods of using chimeric receptor expressing cells, a population of chimeric receptor expressing cells, and pharmaceutical compositions and formulations thereof.

Enhancing ADCC

[00245] In some embodiments, the disclosure provides a method of inducing or enhancing antibody-dependent cellular cytotoxicity (ADCC) of an immune effector cell (c.g., NK cell). ADCC is a multi-tiered process involving coordination and crosstalk of immune cells.

[00246] In some embodiments, a cell expressing a chimeric receptor described herein exhibits induced or enhanced ADCC relative to a cell lacking the chimeric receptor. In some embodiments, the cell expressing a chimeric receptor described herein is an NK cell, such as an NK cell derived from an induced pluripotent cell, and the NK cell exhibits induced or enhanced ADCC against a NK cell-resistant target cell, relative to an NK cell lacking the chimeric receptor. In some embodiments, ADCC is enhanced by 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7- fold, 8-fold, 9-fold or 10-fold. In some embodiments, ADCC is enhanced up to 100-fold. In some embodiments, ADCC is enhanced up to 1000-fold.

[00247] In some embodiments, the chimeric receptors of the present disclosure can be combined in a pharmaceutical composition with a therapeutic antibody. In some embodiments, the therapeutic antibody is an IgGl or an IgG3 antibody. In some embodiments, the therapeutic antibody binds to CD64 on NK cells. In some embodiments, the therapeutic antibody is a bispecific antibody. In some embodiments, the therapeutic antibody is a multispecific antibody. In some embodiments, the therapeutic antibody binds to a tumor antigen selected from the group consisting of CD20, CD30, EGFR, CD19, IL-R, HER2, BCMA, CD123, CD38, PSMA, and CLL1. In some embodiments, the therapeutic antibody comprises an anti-CD20 antibody (e.g., rituximab). In some embodiments, the therapeutic antibody comprises an anti-HER2/neu antibody (e.g., trastuzumab). In some embodiments, the therapeutic antibody comprises an anti- EGFR antibody (e.g., cetuximab). In some embodiments, the therapeutic antibody comprises an anti-CD19 antibody (e.g., tafasitamab, loncastuximab tesirine). In certain embodiments, the chimeric receptor expressing cell of the present disclosure is precomplexed with one or more therapeutic antibody. Cancer Treatment

[00248] In some embodiments, the disclosure provides a method of treating cancer with chimeric receptor expressing cells or pharmaceutical compositions or formulations thereof. In some embodiments, the method comprises administering the chimeric receptor expressing cells, pharmaceutical compositions or formulations described herein to a subject in need thereof. The terms “administration” and “administering,” as used herein, refer to the delivery of a bioactive composition or formulation by an administration route comprising, but not limited to, oral, intravenous, intra-arterial, intramuscular, intraperitoneal, subcutaneous, intramuscular, and topical administration, or combinations thereof. The term includes, but is not limited to, administering by a medical professional and self-administering.

[00249] In some embodiments, a cell expressing a chimeric receptor described herein exhibits enhanced anti-tumor efficacy relative to a cell lacking the chimeric receptor. In some embodiments, the cell expressing a chimeric receptor described herein is an NK cell, such as an NK cell derived from an induced pluripotent cell, and the NK cell exhibits enhanced anti-tumor efficacy against a NK cell-resistant target cell, relative to an NK cell lacking the chimeric receptor.

[00250] Methods for measuring anti-tumor efficacy in vitro and in vivo are known to those of skill in the art and include, for example, in vitro killing assays and implanting tumors into mouse models.

[00251] Cell killing may be assessed by assays known in the art, including but not limited to those described in the examples.

[00252] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced cell killing by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, or about 1000% compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide.

[00253] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced cell killing by between 1% to 5%, between 5% to 10%, between 10% to 20%, between 20% to 30%, between 30% to 40%, between 40% to 50%, between 50% to 60%, between 60% to 70%, between 70% to 80%, between 80% to 90%, between 90% to 100%, or between 100% to 1000% compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide. [00254] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced cell killing by about 1 hour, about 5 hours, about 10 hours, about 20 hours, about 30 hours, about 40 hours, about 50 hours, about 60 hours, about 70 hours, about 80 hours, about 90 hours, about 100 hours, or about 1000 hours compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide.

[00255] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced cell killing by between 1 hour to 5 hours, between 5 hours to 10 hours, between 10 hours to 20 hours, between 20 hours to 30 hours, between 30 hours to 40 hours, between 40 hours to 50 hours, between 50 hours to 60 hours, between 60 hours to 70 hours, between 70 hours to 80 hours, between 80 hours to 90 hours, between 90 hours to 100 hours, or between 100 hours to 1000 hours compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide

[00256] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced specific killing by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, or about 1000% compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide.

[00257] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced specific killing by between 1% to 5%, between 5% to 10%, between 10% to 20%, between 20% to 30%, between 30% to 40%, between 40% to 50%, between 50% to 60%, between 60% to 70%, between 70% to 80%, between 80% to 90%, between 90% to 100%, or between 100% to 1000% compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide.

[00258] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced specific killing by about 1 hour, about 5 hours, about 10 hours, about 20 hours, about 30 hours, about 40 hours, about 50 hours, about 60 hours, about 70 hours, about 80 hours, about 90 hours, about 100 hours, or about 1000 hours compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide.

[00259] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced specific killing by between 1 hour to 5 hours, between 5 hours to 10 hours, between 10 hours to 20 hours, between 20 hours to 30 hours, between 30 hours to 40 hours, between 40 hours to 50 hours, between 50 hours to 60 hours, between 60 hours to 70 hours, between 70 hours to 80 hours, between 80 hours to 90 hours, between 90 hours to 100 hours, or between 100 hours to 1000 hours compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide.

[00260] In some embodiments, a cell expressing a chimeric receptor and/or fusion polypeptide described herein exhibits enhanced specific killing by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, or about 1000% when combined with a dose of a therapeutic antibody, compared to a cell that lacks the chimeric receptor and/ or fusion polypeptide under the same conditions. In some embodiments, the dose of the therapeutic antibody is less than or equal to about 5 pg/mL. In some embodiments, the dose of the therapeutic antibody is less than or equal to about 2.5 pg/mL. In some embodiments, the dose of the therapeutic antibody is less than or equal to about 1.0 pg/mL. In some embodiments, the dose of the therapeutic antibody is less than or equal to about 0.5 pg/mL. In some embodiments, the dose of the therapeutic antibody is less than or equal to about 0.25 pg/mL. In some embodiments, the dose of the therapeutic antibody is less than or equal to about 0.1 pg/mL. In some embodiments, the dose of the therapeutic antibody is less than or equal to about 0.01 pg/mL. In some embodiments, the dose of the therapeutic antibody is about 0.01 to about 5.0 pg/mL. In some embodiments, the dose of the therapeutic antibody is about 0.01 to about 2.5 pg/mL. In some embodiments, the dose of the therapeutic antibody is about 0.01 to about 1.0 pg/mL. In some embodiments, the dose of the therapeutic antibody is about 0.01 to about 0.5 pg/mL. In some embodiments, the dose of the therapeutic antibody is about 0.01 to about 0.25 pg/mL.

DEFINITIONS

[00261] All publications, patents and patent applications, including any drawings and appendices therein, are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent or patent application, drawing, or appendix was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. [00262] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavor to which this specification relates.

[00263] All embodiments of some or any aspect of the disclosure can be used in combination, unless the context clearly dictates otherwise.

[00264] Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to.”

[00265] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. “And” as used herein is interchangeably used with “or” unless expressly stated otherwise. Words using the singular or plural number also include the plural and singular number, respectively.

[00266] Section headings are for convenience only and combination of elements from different sections is contemplated. Additionally, the words “herein,” “above,” “below,” and words of similar import, when used in this application, refer to this application as a whole and not to any particular portions of the application.

[00267] The term “functional variant” refers to a homology (by sequence or structure) of a domain that retains sufficient signaling activity to activate an NK cell.

[00268] The term “sequence identity” refers to the percentage identity of a polypeptide or polynucleotide sequence of interest to a reference sequence, calculated as 100 times the number of exact matches in an optimum alignment of the sequence of interest to the reference sequence divided by the total length of the reference sequence (including gaps). An optimum alignment of the sequences may be generated using the European Molecular Biology Open Software Suite (EMBOSS) needle program available at www.ebi.ac.uk, as described in Maderia et al. Nucleic Acids Res. 47(W1): W636-W641 (2019).

[00269] The term “chimeric receptor” refers to a synthetic polypeptide comprising two or more polypeptides operably linked with at least one polypeptide capable of being expressed on the surface of a cell. [00270] As used herein, "about" will be understood by persons of ordinary skill and will vary to some extent depending on the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill given the context in which it is used, "about" will mean up to plus or minus 10% of the particular value.

[00271] " Amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g. , hydroxyproline, y-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e. , an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g. , homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that function in a manner similar to a naturally occurring amino acid.

[00272] Amino acids can be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, can be referred to by their commonly accepted single-letter codes.

[00273] An "amino acid substitution" refers to the replacement of at least one existing amino acid residue in a predetermined amino acid sequence (an amino acid sequence of a starting polypeptide) with a second, different "replacement" amino acid residue. An "amino acid insertion" refers to the incorporation of at least one additional amino acid into a predetermined amino acid sequence. While the insertion will usually consist of the insertion of one or two amino acid residues, the present larger "peptide insertions," can be made, e.g. insertion of about three to about five or even up to about ten, fifteen, or twenty amino acid residues. The inserted residue(s) may be naturally occurring or non-naturally occurring as disclosed above. An "amino acid deletion" refers to the removal of at least one amino acid residue from a predetermined amino acid sequence. [00274] T 'he "intracellular signaling domain" means any oligopeptide or polypeptide domain known to function to transmit a signal causing activation or inhibition of a biological process in a cell, for example, activation of an immune cell such as an NIC cell. Examples include ILR chain,

[00275] A polypeptide or amino acid sequence "derived from" a designated polypeptide or protein refers to the origin of the polypeptide. In some embodiments, the polypeptide or amino acid sequence which is derived from a particular sequence has an amino acid sequence that is essentially identical to that sequence or a portion thereof, wherein the portion consists of at least 10-20 amino acids, at least 20-30 amino acids, least 30-50 amino acids, or which is otherwise identifiable to one of ordinary skill in the art as having its origin in the sequence.

[00276] Polypeptides derived from another peptide may have one or more mutations relative to the starting polypeptide, e.g., one or more amino acid residues which have been substituted with another amino acid residue or which has one or more amino acid residue insertions or deletions.

[00277] A polypeptide can comprise an amino acid sequence which is not naturally occurring. Such variants necessarily have less than 100% sequence identity or similarity with the starting molecule. In a preferred embodiment, the variant will have an amino acid sequence from about 75% to less than 100% amino acid sequence identity or similarity with the amino acid sequence of the starting polypeptide, more preferably from about 80% to less than 100%, more preferably from about 85% to less than 100%, more preferably from about 90% to less than 100% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) and most preferably from about 95% to less than 100%, e.g., over the length of the variant molecule. In some embodiments, there is one amino acid difference between a starting polypeptide sequence and the sequence derived therefrom. Identity or similarity with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical (i.e., same residue) with the starting amino acid residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.

[00278] As used herein, the term "effective dose" or "effective dosage" is defined as an amount sufficient to achieve or at least partially achieve the desired effect. The term "therapeutically effective dose" is defined as an amount sufficient to cure or at least partially arrest the disease and its complications in a patient already suffering from the disease. Amounts effective for this use will depend upon the severity of the disorder being treated and the general state of the patient's own immune system.

[002791 As used herein, the term "effector cell" or "effector immune cell" refers to a cell involved in an immune response, e.g., in the promotion of an immune effector response. In some embodiments, immune effector cells specifically recognize an antigen. Examples of immune effector cells include, but are not limited to, Natural Killer (NK) cells, B cells, monocytes, macrophages, T cells (e.g., cytotoxic T lymphocytes (CTLs). In some embodiments, the effector cell is an NK cell.

[00280] As used herein, the term "immune effector function" or "immune effector response" refers to a function or response of an immune effector cell that promotes an immune response to a target.

[00281] As used herein, "immune cell" is a cell of hematopoietic origin and that plays a role in the immune response. Immune cells include lymphocytes (e.g., B cells and T cells), natural killer cells, and myeloid cells (e.g, monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes).

[00282] As used herein, a subject "in need of prevention," "in need of treatment," or "in need thereof," refers to one, who by the judgment of an appropriate medical practitioner (e.g., a doctor, a nurse, or a nurse practitioner in the case of humans; a veterinarian in the case of nonhuman mammals), would reasonably benefit from a given treatment (such as treatment with a composition comprising an amphiphilic ligand conjugate)

[00283] As used herein, the terms "linked," "operably linked," "fused", or "fusion", are used interchangeably. These terms refer to the joining together of two more elements or components or domains, by an appropriate means including chemical conjugation or recombinant DNA technology. Methods of chemical conjugation (e.g., using heterobifunctional crosslinking agents) are known in the art as are methods of recombinant DNA technology.

[00284] "Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double- stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences and as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al, Nucleic Acid Res. 19:5081, 1991; Ohtsuka et al, J. Biol. Chem. 260:2605-2608, 1985); and Cassol et al, 1992; Rossolini et al., Mol Cell. Probes 8:91-98, 1994). For arginine and leucine, modifications at the second base can also be conservative. The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene. [00285] Polynucleotides of the present disclosure can be composed of any polyribonucleotide or polydeoxribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double- stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that can be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide can also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

[00286] In some embodiments, the peptides of the disclosure are encoded by a nucleotide sequence. Nucleotide sequences of the disclosure can be useful for a number of applications, including: cloning, gene therapy, protein expression and purification, mutation introduction, DNA vaccination of a host in need thereof, antibody generation for, e.g., passive immunization, PCR, primer and probe generation, and the like.

[00287] As generally used herein, "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.

[00288] "Polypeptide," "peptide", and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

[00289] As used herein, the term "subject" includes any human or non-human animal. For example, the methods and compositions of the present disclosure can be used to treat a subject with a cancer. The term "non-human animal" includes all vertebrates, e.g., mammals and nonmammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.

[00290] The term "sufficient amount" or "amount sufficient to" means an amount sufficient to produce a desired effect, e.g., an amount sufficient to reduce the diameter of a tumor.

[00291] T 'he terms "treat,” "treating," and "treatment," as used herein, refer to therapeutic or preventative measures described herein. The methods of "treatment" employ administration to a subject, in need of such treatment, an engineered cell of the present disclosure. In some embodiments, an engineered cell is administered to a subject in need of an enhanced immune response against a particular antigen or a subject who ultimately may acquire such a disorder, in order to prevent, cure, delay, reduce the severity of, or ameliorate one or more symptoms of the disorder or recurring disorder, or in order to prolong the sunrival of a subject beyond that expected in the absence of such treatment.

EXAMPLES

[00292] The examples in this section are offered by way of illustration, and not by way of limitation. The following examples are presented as exemplary embodiments of the invention. They should not be construed as limiting the broad scope of the invention.

Example 1: In vitro Functional Testing

Evaluation of chimeric receptor expression in HEK or NK cell lines

[00293] For each CD64 chimeric receptor, a plasmid encoding the chimeric receptor is transduced using nucleofection, or a lentivirus encoding the chimeric receptor is transduced, into human embryonic kidney cells (293T HEK) or NK cells (NK-92 cell line), followed by puromycin selection. Cell-surface expression of the chimeric receptor is assessed by flow cytometry by staining for an HA-tag (located between CD8 leader sequence and scFv). [00294] Cell lines generated above that exhibit chimeric receptor expression are assessed for functional activity using the following assays:

Expression of chimeric receptor constructs in iPSC derived NK cells:

[00295] Functional chimeric receptors identified using NK92 cell line are expressed in iPSC- derived NK cells and validated using in vitro functional assays.

[00296] Expression: Chimeric receptor constructs are used to transfect human iPSC line and chimeric receptor -expressing cells are enriched by puromycin expression. Cell surface expression is validated by flow cytometry using a HA-tag.

Example 2: CD64 Chimeric Receptor Enhances ADCC in WT and CISH KO iNKs

[00297] To demonstrate that the chimeric receptors described herein induce or enhance antibody-dependent cellular cytotoxicity (ADCC) of NK cells, an exemplary chimeric receptor construct was expressed in wild-type (WT) NK cells derived from induced pluripotent stem cells (iPSCs) (hereinafter “WT iNK” cells) or iNK cells that were genetically engineered to knock-out both alleles of the CISH gene (hereinafter “CISH KO iNK” cells).

[00298] Briefly, WT iNK or CISH KO iNK cells were transduced with lentivirus to coexpress an exemplary CD64 chimeric receptor and IL-15: CD64-NKTM-linker-2B4ICD -linker- CD3zeta- Linker-P2A-GM_CSFR Signal Peptide-hIL15-IL15 SG Linker-IL15RA (hereinafter “CD64-NKTM-2B4-CD3zeta-IL15”). Expression was checked by flow cytometry (data not shown).

[00299] WT iNK and CISH KO iNK cells were then added to BT474 cells seeded in 2D the day prior at a ratio of 2: 1. Trastuzumab was precomplexed at 10 pg/mL with the target BT474 cells prior to addition of the WT iNK or CISH KO iNK cells.

[00300] As shown in FIG. 1, WT and CISH KO iNK cells expressing CD64-NKTM-2B4- CD3zeta-IL15 exhibited enhanced killing upon mAb stimulation, relative to without mAb stimulation (FIG. 1). Further, CISH KO iNK cells demonstrated enhanced killing relative to WT iNK cells, with or without mAb stimulation, respectively (FIG. 1).

[00301] Taken together this data demonstrates that expression of a CD64-CAR, such as CD64-NKTM-2B4-CD3zeta-IL15, enhances ADCC in both WT and CISH KO cells. Example 3: CD64 Chimeric Receptor Enhances ADCC in Dose Dependent Manner

[00302] To demonstrate that the CD64 chimeric receptors described herein enhance ADCC in 3D, an exemplary NK-specific chimeric receptor construct (CD64-NKTM-2B4-CD3zeta-IL15) was expressed in CISH KO iNK cells and a 3D spheroid assay using FaDu pharyngeal carcinoma cells, a NK cell resistant solid tumor, was performed with or without cetuximab.

[00303] Briefly, CISH KO iNK were transduced with retrovirus to stably expressly the CD64- NKTM-2B4-CD3zeta-IL15 construct, and cells were sorted for pure CAR population. FaDu spheroids were generated and stained with cell tracker red. The sorted CISH KO effector cells were precomplexed with cetuximab and then added to spheroids.

[00304] As shown in FIG. 2A, the CD64-NKTM-2B4-CD3zeta-IL15 construct alone did not result in improved killing compared to untransduced CISH KO iNKs, as indicated by little to no deterioration of spheroid structural integrity (FIG. 2A). In addition, untransduced CISH KO iNK cells did not exhibit ADCC, as indicated by little to no deterioration of spheroid structural integrity (FIG. 2A). However, when the target FaDu cells were precomplexed with 10 pg/mL of cetuximab, the CD64-NKTM-2B4-CD3zeta-IL15 construct enhanced ADCC against FaDu spheroids after 72 hour co-culture of CISH KO iNK cells and FaDu spheroids (E:T 2.5: 1), as indicated by pronounced deterioration of spheroid structural integrity (FIG. 2A).

[00305] The enhanced ADCC observed upon expression of the CD64-NKTM-2B4-CD3zeta- IL15 construct was also demonstrated to be dose dependent. Specifically, when the target FaDu cells were precomplexed with 10 pg/mL of cetuximab, the CD64-NKTM-2B4-CD3zeta-IL15 construct enhanced ADCC against FaDu spheroids after 72 hour co-culture of CISH KO iNK cells and FaDu spheroids (E:T 10:1) as indicated by complete deterioration of spheroid structural integrity. Moreover, this effect was dose dependent because the deterioration of spheroid structural integrity at 10 pg/mL of cetuximab was more pronounced than when the target FaDu cells were precomplexed with 1 pg/mL of cetuximab under the same conditions (FIG. 2B). Expression of the CD64-NKTM-2B4-CD3zeta-IL15 construct enhanced ADCC against FaDu spheroids at various effectontarget cell ratios, relative to untransduced cells (FIG. 2C-FIG. 2E). Antibody alone had minimal effect (FIG. 2F).

[00306] These results demonstrated that expression of a CD64-CAR, such as CD64-NKTM- 2B4-CD3zeta-IL15, enhances ADCC against FaDu spheroids in a dose dependent manner. Example 4: CD64 Chimeric Receptor ADCC Enhancement is Comparable to hnCD16 [00307] This example demonstrates that the ADCC enhancement achieved with iNK cells expressing the CD64 chimeric receptor constructs provided herein is comparable to the amount of ADCC observed with iNK cells engineered to express hnCD16, a model that has been shown to exhibit enhanced ADCC against multiple tumor targets (see, e.g., Zhu et al., Blood, 2020; 35(6):399-410).

[00308] Briefly, CISH KO iNK were electroporated with mRNA encoding CD64-NKTM- linker-TLR2-linker-CD3zeta (hereinafter “CD64-NKTM-TLR2-CD3zeta” or “CD64-CAR2”) or hnCD16. The following day, the CISH KO iNK cells were precomplexed with trastuzumab and added as effectors to BT474 spheroids expressing mKate2 (E:T 20: 1). ADCC was measured for 72 hours following addition of precomplexed effectormAb cells to targets. The results demonstrated that the CD64-NKTM-TLR2-CD3zeta (“CD64-CAR2”) construct enhanced ADCC at levels comparable to hnCD16 (E:T 20: 1), as indicated by the deterioration of spheroid structural integrity (FIG. 3A) and quantified in the line graph (FIG. 3B). In parallel, CAR expression was measured, and expression of the CD64-NKTM-TLR2-CD3zeta (“CD64-CAR2”) chimeric receptor at 4, 48, and 72 hours was even lower than expression of hnCD16 (FIG. 3C). [00309] These results demonstrated that expression of a CD64 chimeric receptor construct, such as CD64-NKTM-TLR2-CD3zeta (“CD64-CAR2”), enhances ADCC at levels comparable to hnCD16.

Example 5: CD64 Chimeric Receptors Have Greater ADCC Enhancement with Low Antibody Doses

[00310] This example demonstrates that iNK cells expressing the CD64 chimeric receptor constructs provided herein mediate enhanced tumor cell killing at lower antibody concentrations compared to iNK cells engineered to express hnCD16, or hCD16.

[00311] Briefly, CISH KO iNK were electroporated with mRNA encoding (1) CD64-NKTM- linker-TLR2-linker-CD3zeta (hereinafter “CD64-NKTM-TLR2-CD3zeta” or “CD64-CAR2”); (2) hCD16; or (3) hnCD16. The following day, the CISH KO iNK cells were precomplexed with trastuzumab and added as effectors to BT474 spheroids expressing mKate2 (E:T 10:1). Expression of the constructs was measured at the start of the killing assay (FIG. 4A), and NK cell killing was measured by assessing reduction of the mKate2-expressing BT474 spheroid tumor targets with trastuzumab concentration ranges from 0.01 pg/mL to 10 pg/mL (FIG. 4B). [00312] ADCC was measured for 48 hours following addition of precomplexed effector: m Ab cells to targets. The results demonstrated that CD64-CAR2 exhibited robust ADCC across the antibody concentrations, whereas hCD16 and hnCD16 only exhibited robust ADCC at the highest antibody concentration (FIG. 4B). Notably, the enhanced ADCC was observed despite lower expression of CD64-CAR2 relative to hnCD16 and hCD16 (FIG. 4B).

[00313] Similar results were observed for CD64 chimeric receptors when CISH KO iNK were electroporated with mRNA encoding CD64-CAR2 or CD64-CD16TM-linker-CD16 (hereinafter “CD64-CD16”) relative to hCD16 and hnCD16 constructs. Specifically, ADCC was enhanced for iNK cells expressing CD64-CAR2 and CD64-16, even at low concentrations of the therapeutic antibody (FIG. 5 A and FIG. 5B). In contrast, iNK cells expressing hCD16 or hnCD16 exhibited a dose response to the therapeutic antibody, and had lower amounts of ADCC for lower concentrations (<10 pg/mL) of the antibody (FIG. 5C and FIG. 5D).

[00314] These results demonstrate that CD64 chimeric receptors have greater ADCC enhancement with low doses of a therapeutic antibody (e.g., trastuzumab), relative to hCD16 or hnCD16.

Example 6: CD64 Chimeric Receptors with NKG2D or TLR2 Transmembrane Domains and TLR2 Signaling Domain Exhibit Robust ADCC

[00315] This example demonstrates that alternative transmembrane domains can be used without affecting the function of the CD64 chimeric receptor, and that constructs with a TLR2 signaling domain exhibited enhanced ADCC.

[00316] Briefly, CISH KO iNK were electroporated with mRNA encoding (1) CD64-NKTM- linker-TLR2-linker-CD3zeta (hereinafter “CD64-NKTM-TLR2-CD3zeta” or “CD64-CAR2”);

(2) CD64-TLR2TM-TLR2MP-TLR2-linker-CD3zeta (hereinafter “CD64-TLR2TM-TLR2- CD3zeta” or “CD64-CAR3”); or (3) CD64-NKTM-linker-2B4-linker-CD3zeta (hereinafter “CD64-NKTM-2B4-CD3zeta” or “CD64-CAR4”). The following day, the CISH KO iNK cells were precomplexed with trastuzumab and added as effectors to BT474 spheroids expressing mKate2 (E:T 20: 1) (FIG. 6A). Expression of the constructs was measured at the start of the killing assay (FIG. 6B). [00317] The results demonstrated that iNK cells expressing CD64-CAR2 and CD64-CAR3 exhibited similar ADCC enhancement, which was more robust than iNK cell expressing CD64- CAR4.

Example 7: Serum IgG Inhibited CD64 Chimeric Receptor and CD16 Receptors, Without Stopping ADCC Killing

[00318] The example demonstrates that introduction of serum IgG inhibits, but does not stop ADCC killing for both the CD64 chimeric receptors and the CD16A receptor.

[00319] Briefly, CISH KO iNK were electroporated with mRNA encoding (1) CD64-NKTM- linker-TLR2-linker-CD3zeta (hereinafter “CD64-NKTM-TLR2-CD3zeta” or “CD64-CAR2”);

(2) CD64-CD16TM-linker-CD16 (hereinafter “CD64-CD 16”); (3) hCD16; or (4) hnCD16. The following day, the CISH KO iNK cells were precomplexed with trastuzumab and added as effectors to BT474 spheroids expressing mKate2 (E:T 20: 1). NK cell killing was measured with IgG concentration ranges from 0.00 mg/mL to 8 mg/Ml and demonstrated that introduction of serum IgG inhibits, but does not stop ADCC killing for both the CD64 chimeric receptors and the CD16A receptor (FIG. 7A-7F, FIG. 8A-8E). Expression data indicated the CD64-CAR2 was approximately 30% of the other constructs (data not shown).

[00320] Taken together, these results demonstrate that the CD64 chimeric receptors and the CD16A receptor exhibit similar responses to serum blockage.

Example 8: Knock-in of CD64 Chimeric Receptor Enhance ADCC

[00321] This example demonstrates that iNK cells with knock-in (KI) of the exemplary CD64 chimeric receptors CD64-NKTM-linker-TLR2-linker-CD3zeta + IL15 receptor fusion (hereinafter “CD64-CAR5”) or CD64-TLR2TM-TLR2MP-TLR2-linker-CD3zeta + IL15 receptor fusion (hereinafter “CD64-CAR6”) exhibit robust ADCC.

[00322] Briefly, KI of the CD64-CAR5 or the CD64-CAR6 cassette was performed on iPSCs using CRISPR at the AAVS1 locus, and then KI iPSC were bulk-sorted for CD64 expression.

Cells were then differentiated into iNK cells, and expanded by stimulating the iNK cells using 4- 1BBL and IL -21 expressing K562 antigen-presenting cells (“sAPCs”). Generally, stimulation was done at a 2: 1 ratio of sAPC to iNK for 7 days using 10E6 iNK cells and 20E6 sAPCs in a 6 well GREx. Prior to adding the iNK cells to the target cells, iNK were mixed with trastuzumab. [00323] The results demonstrated that ADCC was enhanced for iNK cells with knock-in of CD64-CAR5 and CD64-CAR6, relative to the parental clone without a CD64 knock-in.

Consistent ADCC enhancement in CD64-CAR6 KI iNKs. For example, NK cell mediated killing was measured after 72 hours (E:T 1 : 1) and both CD64-CAR5 and CD64-CAR6 exhibited enhanced ADCC, with CD64-CAR6 having a greater and dose dependent effect (FIG. 9A-FIG. 9C). While ADCC of BT474 spheroids expressing mKate2 was enhanced in the presence of trastuzumab (an anti-HER2 antibody), rituximab (an anti-CD19 antibody) did not improve killing, demonstrating that the increase in cell killing was not due to activation by Fc receptor binding (FIG. 9A-FIG. 9C).

[00324] The enhanced ADCC was also observed following stimulation with sAPCs at a 1 : 1 ratio (e.g., 10E6 iNK cells stimulated by 10E6 sAPCs in a 6 well GREx) for 3 days. Specifically, NK cell mediated killing was measured after 24 hours (E:T 2.5:1 and 1 :1) and both CD64-CAR5 and CD64-CAR6 exhibited enhanced ADCC, with CD64-CAR6 having a greater and dose dependent effect (FIG. 10A - FIG. 10C. FIG. 11 A - FIG. 11C). In addition, serum IgG was found to not affect baseline killing in iNKs (FIG. 12A - FIG. 12C), and inhibit ADCC mediated killing (FIG. 13A - FIG. 13C) .

[00325] In addition, it was observed that CD64 is more highly expressed in iPSCs and iNKs with a knock-in of the CD64-CAR6 cassette than knock-in of the CD64-CAR5 cassette, and . expression of other components of the KI cassette, such as IL-15RF were also increased (data not shown).

[00326] Taken together, these results demonstrate that knock-in of the exemplary CD64 chimeric receptors CD64-CAR5 and CD64-CAR6 enhance ADCC.

* * *

[00327] The embodiments described above are intended to be merely exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the invention and are encompassed by the appended claims.

Claims

1. A chimeric receptor comprising from N-terminus to C-terminus:

(ii) a transmembrane domain; and

2. The chimeric receptor of claim 1, wherein the IgG Fc receptor is selected from CD16, CD32a, CD32b, CD32c, and CD64.

3. The chimeric receptor of claim 1, wherein the polypeptide comprises an ectodomain domain of CD64.

4. The chimeric receptor of claim 1, wherein the polypeptide comprises an ectodomain domain of CD 16, or variant thereof.

5. The chimeric receptor of claim 1, wherein the polypeptide derived from the IgG Fc receptor comprises a sequence selected from SEQ ID NO: 38.

6. The chimeric receptor of any one of claims 1-5, wherein the transmembrane domain is a transmembrane domain of DNAM1, CD64, CD32a, CD32c, 2B4, CD8, CD4, CD3, NTB-A, CD28, IL-2R beta, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, IL- 1R or IL-18R, NKG2D, or a functional variant thereof.

7. The chimeric receptor of claim 6, wherein the transmembrane domain of NKG2D is in reverse orientation, optionally wherein the transmembrane domain of NKG2D in reverse orientation comprises the amino acid sequence of SEQ ID NO: 36.

8. The chimeric receptor of any one of claims 1-7, wherein the TIR signaling domain is a signaling domain of a Toll-like receptor (TLR) polypeptide.

9. The chimeric receptor of claim 8, wherein the TIR signaling domain is a signaling domain of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, or TLR10.

10. The chimeric receptor of claim 9, wherein the TIR signaling domain is a signaling domain of TLR2.

11. The chimeric receptor of claim 10, wherein the signaling domain of TLR comprises the amino acid sequence set forth in SEQ ID NO: 25.

12. The chimeric receptor of claim 11, wherein the TIR signaling domain comprises a sequence selected from SEQ ID NOs: 25, 118, 120, 122, 124, 126, 128, 130, 132 and 134.

13. The chimeric receptor of any one of claims 1-7, wherein the TIR signaling domain is a signaling domain of an interleukin- 1 receptor (IL-1R) polypeptide.

14. The chimeric receptor of claim 13, wherein the TIR signaling domain is a signaling domain of IL-lR, IL-18R, IL-1R4, IL-1R6, IL-1R3, IL-1R7, IL-18R, IL-1R9, or IL-lRlO.

15. The chimeric receptor of claim 14, wherein the TIR signaling domain comprises a sequence selected from SEQ ID NOs: 136, 138, 140, 142, 144, 146, 148, 150, and 152.

16. The chimeric receptor of any one of claims 1-15, wherein the cytoplasmic domain further comprises an intracellular signaling domain.

17. The chimeric receptor of claim 16, wherein the intracellular signaling domain is a signaling domain of CD3zeta or CD 137.

18. The chimeric receptor of claim 16, wherein the intracellular signaling domain is a signaling domain of CD3zeta, and wherein the signaling domain of CD3zeta comprises the amino acid sequence set forth in SEQ ID NO: 27.

19. The chimeric receptor of any one of claims 16-18, wherein the intracellular signaling domain is operably linked to the TIR signaling domain with or without a linker.

20. The chimeric receptor of claim 19, wherein the C-terminus of the TIR signaling domain is operably linked to the N-terminus of the intracellular signaling domain via a Gly-Ser linker.

21. The chimeric receptor of claim 1, wherein

(i) the extracellular domain comprises a polypeptide derived from CD64 ectodomain; (ii) the transmembrane domain is a transmembrane domain of CD28, TLR2, CD64 or NKG2D; and

(ii) the cytoplasmic domain comprises a signaling domain of TLR2.

22. The chimeric receptor of claim 21, wherein the cytoplasmic domain further comprises a signaling domain of CD3zeta.

23. The chimeric receptor of claim 1, comprising:

(i) a CD64 ectodomain, a CD28 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain;

(ii) a CD64 ectodomain, a CD64 transmembrane domain, a TLR2 signaling domain, and a CD3zeta signaling domain; or

24. The chimeric receptor of any one of claims 1-23, wherein the C-terminus of the extracellular domain is operably linked to the N-terminus or C-terminus of the transmembrane domain without a linker.

25. The chimeric receptor of claim 24, wherein the C-terminus of the extracellular domain is operably linked to the N-terminus or C-terminus of the transmembrane domain with a linker or a hinge domain.

26. The chimeric receptor of claim 25, wherein the hinge domain is a hinge region of CD8a.

27. The chimeric receptor of claim 26, wherein the hinge region of CD8a comprises the amino acid sequence set forth in SEQ ID NO: 154.

28. The chimeric receptor of any one of claims 1-27, wherein the N-terminus or C-terminus of the transmembrane domain is operably linked to the N-terminus of the cytoplasmic domain, with or without a linker.

29. The chimeric receptor of claim 28, wherein the transmembrane domain is operably linked to the cytoplasmic domain with a Gly-Ser linker.

30. The chimeric receptor of claim 1, comprising an amino acid sequence selected from SEQ ID NOs: 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, and 102.

31. A polynucleotide comprising a nucleotide sequence encoding the chimeric receptor of any one of claims 1-30.

32. A population of cells comprising an immune cell comprising the chimeric receptor of any one of claims 1-30 or the polynucleotide of claim 31.

33. The population of cells of claim 32, wherein the immune cell is a natural killer (NK) cell.

34. The population of cells of claim 33, wherein the NK cell is an induced pluripotent stem cell-derived natural killer (iPSC-NK) cell.

35. The population of cells of any one of claims 32-34, wherein the immune cell comprises a chimeric antigen receptor (CAR).

36. The population of cells of claim 35, wherein the CAR comprises an antigen binding domain.

37. The population of cells of claim 36, wherein the antigen binding domain is specific for a cancer antigen.

38. The population of cells of any one of claims 32-37, wherein the immune cell further comprises an IL-15 polypeptide.

39. The population of cells of claim 38, wherein the IL-15 polypeptide is a fusion protein of a human IL-15 polypeptide operably linked to a human IL-15Ra polypeptide, with or without a linker.

40. The population of cells of claim 39, wherein the human IL-15 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 17, and the human IL-15Ra polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 21.

41 . The population of cells of claim 39, wherein the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 29.

42. The population of cells of any one of claims 32-41, wherein the immune cell comprises homozygous inactivating mutations in a cytokine-inducible SH2-containing protein (CISH) gene.

43. The population of cells of any one of claims 32-41, wherein the immune cell is CISH -/-.

44. The population of cells of any one of claims 32-43, wherein the chimeric receptor is stably expressed.

45. A population of cells comprising the polynucleotide of claim 31, wherein the polynucleotide is knocked-in to the genome of the cell.

46. A pharmaceutical composition comprising the population of cells of any one of claims 32-45.

47. The pharmaceutical composition of claim 46, further comprising an effective amount of a therapeutic antibody.

48. The pharmaceutical composition of claim 47, wherein the therapeutic antibody comprises trastuzumab.

49. The pharmaceutical composition of claim 47, wherein the therapeutic antibody comprises cetuximab.

50. The pharmaceutical composition of any one of claims 47 to 49, wherein the population of cells is pre-complexed with the therapeutic antibody.

51. A method of treating cancer in a subject in need thereof, comprising administering the pharmaceutical composition of any one of claims 46 to 50 to the subject.

52. A method of enhancing antibody-dependent cellular cytotoxicity (ADCC) of an NK cell, comprising engineering the NK cell to express the chimeric receptor of any one of claims 1-30.

53. The method of claim 52, wherein the NK cell comprises a CAR.

54. A method of enhancing anti-tumor efficacy of a CAR-expressing immune cell, comprising engineering the CAR-expressing immune cell to express the chimeric receptor of any one of claims 1-30, thereby enhancing the anti -turn or efficacy of the CAR-expressing immune cell.

55. The method of claim 54, further comprising administering an effective amount of a therapeutic antibody.

56. The method of claim 55, wherein the therapeutic antibody comprises trastuzumab.

57. The method of claim 55, wherein the therapeutic antibody comprises cetuximab.

58. The method of any one of claims 55 to 57, wherein the CAR-expressing immune cell is pre-complexed with the therapeutic antibody prior to administration.